UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

☒

Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

 

For the fiscal year ended December 31, 2022

or

☐

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

 

For the transition period from _______________ to _______________

 

Commission file number 000-53554

 

DAIS CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

New York

 

14-1760865

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

 

11552 Prosperous Drive

Odessa, Florida

 

33556

(Address of Principal Executive Offices)

 

(Zip Code)

 

(727) 375-8484

(Registrant’s Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Name of Each Exchange on Which Registered

None

 

None

 

Securities registered pursuant to Section 12(g) of the Act:

 

(Title of Class)

Common Stock, par value $0.01 per share

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐      No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐      No ☒

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒      No ☐

 

Indicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that registrant was required to submit such files. Yes ☒      No ☐

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒

 

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large, accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large, accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☒

 

Emerging growth company

☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐      No ☒

 

The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant as of December 31, 2022 was $675,068 based on the closing price of $0.098 per share of Dais Corporation common stock as quoted on the OTC Pink Marketplace and a public float of 6,888,445 on that date.

 

On May 26, 2023, there were 20,149,365 shares of the registrant’s common stock outstanding.

 

 

 

 

TABLE OF CONTENTS

 

PART I

 

 

 

 

 

ITEM 1.

BUSINESS.

 

4

 

 

 

 

 

 

ITEM 1A.

RISK FACTORS.

 

8

 

 

 

 

 

 

ITEM 1B.

UNRESOLVED STAFF COMMENTS.

 

8

 

 

 

 

 

 

ITEM 2.

PROPERTIES.

 

8

 

 

 

 

 

 

ITEM 3.

LEGAL PROCEEDINGS.

 

9

 

 

 

 

 

 

ITEM 4.

MINE SAFETY DISCLOSURES

 

9

 

 

 

 

 

 

PART II

 

 

 

 

 

ITEM 5.

MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES.

 

10

 

 

 

 

 

 

ITEM 6.

SELECTED FINANCIAL DATA.

 

11

 

 

 

 

 

 

ITEM 7.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION.

 

11

 

 

 

 

 

 

ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

20

 

 

 

 

 

 

ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

 

20

 

 

 

 

 

 

ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

 

20

 

 

 

 

 

 

ITEM 9A.

CONTROLS AND PROCEDURES.

 

20

 

 

 

 

 

 

ITEM 9B.

OTHER INFORMATION.

 

20

 

 

 

 

 

 

PART III

 

 

 

 

 

ITEM 10.

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

 

21

 

 

 

 

 

 

ITEM 11.

EXECUTIVE COMPENSATION.

 

23

 

 

 

 

 

 

ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

 

25

 

 

 

 

 

 

ITEM 13.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS; AND DIRECTOR INDEPENDENCE.

 

26

 

 

 

 

 

 

ITEM 14.

PRINCIPAL ACCOUNTING FEES AND SERVICES

 

28

 

 

 

 

 

 

PART IV

 

 

 

 

 

ITEM 15.

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

 

29

 

 

 
2

Table of Contents

 

Introductory Comments

 

Throughout this Annual Report on Form 10-K, the terms “we,” “us,” “our,” “the Company,” “our Company,” and “DLYT,” refer to Dais Corporation, a New York corporation (formerly known as ‘Dais Analytic Corporation’).

 

PART I

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, forward-looking statements are identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions intended to identify forward-looking statements. Such statements include, without limitation, statements regarding:

 

 

●

our need for, and our ability to raise, additional equity or debt financing on acceptable terms, if at all;

 

●

our ability to continue as a going concern;

 

●

our need to take strong cost reduction measures, possibly cease operations on commercial or development programs, or sell our operating assets (each an option or a mix of all), if we are unable to obtain sufficient additional financing;

 

●

our belief that we will have sufficient liquidity to finance normal operations for the foreseeable future;

 

●

the options we may pursue considering our financial condition;

 

●

the amount of cash necessary to operate our business;

 

●

our plans and expectations with respect to our continued operations;

 

●

the expected development and success of new instrument and consumables product offerings;

 

●

the expected expenses of, and benefits and results from, our research and development efforts;

 

●

the expected benefits and results from our collaboration programs, strategic alliances, and joint ventures;

 

●

general economic conditions;

 

●

the anticipated future financial performance and business operations of our company;

 

●

our reasons for focusing our resources on the market for nano-structured polymer technology materials;

 

●

the price volatility of the common stock;

 

●

the historically low trading volume of the common stock;

 

●

our ability to attract and retain qualified personnel;

 

●

unanticipated litigation and the outcome of existing litigation;

 

●

our ability to do business in China and elsewhere overseas;

 

●

our ability to compete with current and future competitors;

 

●

the trustworthiness of our counterparties to fulfill their obligations;

 

●

our ability to commercialize our intellectual property;

 

●

Our ability to settle past debt in a satisfactory manner to the Company and its debt holders, I.e., senior secured note holder, convertible note holders, and overdue accounts payable holders.

 

●

other factors discussed in our other filings made with the Commission.

 

These forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements, expressed or implied, by such forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this Annual Report on Form 10-K. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this Annual Report on Form 10-K to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. Factors that could cause or contribute to differences in our future financial and other results include those discussed in the risk factors set forth in Part I, Item 1A of this Annual Report on Form 10-K as well as those discussed elsewhere in this Annual Report on Form 10-K. We qualify all of our forward-looking statements by these cautionary statements.

 

 
3

Table of Contents

 

ITEM 1. BUSINESS.

 

Throughout this document we may use the following terms: Aqualyte™, ConsERV™, NanoClear™, PolyCool™ and NanoAir™ , all of which are unregistered trademarks of the Company.

 

Overview

 

Dais Corporation (“Dais”, “us,” “we,”, the “Company”) is a proprietary, nanotechnology polymer materials company. Nanotechnology involves studying and working with matter on an ultra-small scale. Doing this is where the Company built features and properties into its platform of nanomaterial sold under the brand name “Aqualtye™. Aqualyte™ is used to enable new product variants we believe are better than traditional products which use energy consuming and break-able components. Aqualyte™ itself, is marketed to OEMs to create differentiated products, while the second product is a fixed plate energy recovery ventilator called ConsERV, which we believe is useful in meeting building indoor fresh air requirements while saving energy and lowering emissions for most forms of heating, ventilation, and air conditioning (HVAC) equipment. We continue to develop other nano-structured polymer technology applications in HVAC/Refrigeration, energy, food services and wastewater treatment industries.

 

Corporate History

 

We were incorporated as a New York corporation on April 8, 1993, as The Dais Corporation. The Company was formed to develop new, cost-effective polymer materials for various applications, including providing a lower cost membrane material for Polymer Electrolyte Membrane fuel cells. We believe our research on materials science has yielded technological advances in the field of selective ion transport polymer materials. In December 1999, the Company purchased the assets of Analytic Power Corporation, in March 2002, the Company sold substantially all its fuel cell assets to Chevron, a large U.S. oil company for a combination of cash and the assumption by such company of certain of the Company’s obligations and began working to commercialize the attributes and features of the nanomaterials developed since formation. In November of 2018, the board of directors unanimously voted to change the name of the Company from Dais Analytic Corporation to Dais Corporation (the “Name Change”). The Name Change took effect with FINRA on February 27, 2019.

 

On November 2, 2018, the shareholders of the Company approved an increase in the authorized common shares of the company from 240,000,000 shares to 340,000,000 shares. On March 14, 2019, the shareholders approved an increase in authorized common shares from 340,000,000 shares to 1,100,000,000 shares. In July 2019, the shareholders of the Company approved a reverse stock split of the issued and outstanding shares of the Company’s common stock at the ratio ranging from one-for-500 to one-for-2,000. On October 31, 2019, the Company amended its Certificate of Incorporation to reflect a one-for-2,000 reverse stock split of the Company’s common stock. The reverse split was effective December 6, 2019. All share and per share data have been retroactively restated in this annual report and the accompanying financial statements and footnotes to reflect the effects of the reverse split.

 

Our Technology

 

We use proprietary nanotechnology to reformulate thermoplastic polymers. Nanotechnology involves studying and working with matter on an ultra-small scale. Polymers are chain-like plastic molecules used in diverse products such as Dacron, Teflon, and polyurethane. Thermoplastic is a plastic (deformable) polymer material that melts to a liquid when heated and solidifies when cooled and is able to transition repeatedly between these states. Our reformulated polymers have properties that allow them to be used in unique ways, and we call the resulting material Aqualyte™.

 

 
4

Table of Contents

 

The Company believes the attributes of its Aqualyte™ platform of nanomaterial create a catalyst for change:

 

 

●

Consume less energy and release less CO2 into the atmosphere

 

●

Replace moving parts to increase operational lifetime

 

●

Provide strong pathogen protection (COVID) and lower allergy/asthma triggers

 

●

Reduce operating costs for increased ventilation rates shown in 3rd party testing to improve cognitive performance by 101% on average.

 

●

Extend useable life of food and other organic materials

 

●

Clean most forms of contaminated wastewater to levels up to one-hundred times greater than noted in the Clean Water Act of 1970.

 

Our Products

 

The Company uses its knowledge of the Aqualyte nanomaterial to integrate it into traditional or new product form factors. It is management’s belief based on 3rd party industry or independent test results, the Company’s own testing, or data from customer use, that the benefits address the growing market needs resulting from, but not limited to, the drivers of climate change as well as those needs created by the pandemic.

 

Nanomaterial Platform - Aqualyte™

 

The Aqualyte Nanomaterial is made from commercially available polymer resin and industrial grade solvents which are mixed using a proprietary process with traditional industrial equipment. Our process creates a modified resin with key features and attributes that can be used to offer different properties to multiple products.

 

The Company sells Aqualyte to skilled OEMs using its features and properties to create new and/or improved products in a range of applications. The Company continues to develop next generation versions of its Aqualyte nanomaterial working to increase existing performance, add new features, and improve cost.

 

ConsERV™

 

We continue to expand sales channels to drive growth of revenues of our ConsERV product. ConsERV is an HVAC energy conservation product which should, according to various tests, save energy and operating costs on HVAC equipment, lower CO2 emissions and allow HVAC systems to be 20% - 67% smaller, reducing peak energy usage while simultaneously improving indoor air quality. This product makes most forms of HVAC systems operate more efficiently.  ConsERV generally works in combination with existing HVAC systems, to provide improved ventilation air in buildings. ConsERV uses a fixed-plate enthalpy exchanger (the “core”) constructed with our nanotechnology polymer. When compared to similar competitive products, we believe, based on tests conducted by the Air-conditioning, Heating and Refrigeration Institute (AHRI), a leading industry association, ConsERV maintains an industry leading position in the management of latent heat.

 

The Company began actively rolling out an updated ConsERV product line in 4Q, 2021. The updated line addresses market requested updates and features.

 

The sales channels for ConsERV continue to expand across North America and include private labeling efforts. The Company has and continues to negotiate arrangements with independent sales/engineering representatives in multiple regions across North America who in turn target architects and specifying engineers, select OEMs, utility sponsored programs, and sophisticated users of HVAC equipment.

 

We believe the growth initiatives and what we perceive as changes in the ERV market will allow the company to address well over fifty percent of the addressable North American market for ConsERV.

 

We continue to have targeted discussions with identified companies in the European Union interested in buying and distributing both Aqualyte nanomaterial for use in their ERV cores as well as selling Dais produced ConsERV cores. To help us expand our capabilities in the reported high growth HVAC markets in Southeast Asia, Dais qualified a Chinese manufacturing company to produce ConsERV cores using Aqualyte membrane to meet the growing demand for ConsERV systems in the Region.

 

The Company expects this trend of growing ConsERV system, core, and Aqualyte nanomaterial revenues to continue into 2023 and beyond.

 

Dais continues to respond to market interests by developing additional products that use our nanotechnology to save energy, provide clean water, protect health, and generally promote a more sustainable future.

 

Strategic Partnerships

 

Currently the Company is engaged with a multi-national conglomerate developing a line of products within the Company’s defined and proven uses of its nano polymer's capabilities, We expect, if all continues well, an uptick in revenues from this effort no later than the end of the 2nd quarter of 2024.

 

 
5

Table of Contents

 

Our Patents

 

Dais has owned 25 granted patents over its corporate history, some of which have reached the end of their enforceable term. As of December 31, 2022, Dais owns the active, enforceable rights to eleven U.S. patents, five Chinese patents, two Hong Kong patents, and three Patent Cooperation Treaty (“PCT”) applications that are still being examined. These patents relate to, or are applications of, our nano-structured polymer materials that perform functions such as ion exchange and modification of surface properties. 

 

The company also owns multiple utility patents that cover inventions that are new, improvements and useful processes including the design and fabrication of devices or approaches that use properties of the polymers described above for HVAC, energy, food preservation, and water treatment applications. Dais owns the rights to a new US Patent issued in 2022:

 

 

1.

U.S. Patent No. 11,331,628 – Vapor condenser enhanced by membrane evaporation.  This patent was issued May 17, 2022 and the patent term ends on or about August 29, 2038.

 

2.

C.N. Patent No. 108,430,606B – Evaporative chilling systems and methods using a selective transfer membrane. This patent was issued November 2, 2021, and the patent term ends on or about October 7, 2036.

 

Dais has been notified that the following Application will be granted full US patent status in 2022:

 

 

1.

US20200330923A1–Vapor condenser enhanced by membrane evaporation

 

Additional patent applications are being examined that are not yet publicly visible in the patent system and will be revealed at the appropriate time. Patents may or may not be granted on any of the above applications. We also seek to protect our proprietary intellectual property, including intellectual property that may not be patented or patentable, in part by entering into confidentiality agreements with our current and prospective strategic partners and employees.

 

Manufacturing

 

The Company currently uses a mix of in-house and outsourced assembles for its nanomaterial and product (ConsERV) needs.

 

For future expansion and high-volume scale-up, the Company is actively looking at the costs and merits of organically scaling v. moving to a ‘near 100% outsourced’ model at the most optimum way to grow.  Nonetheless, the Company continues to strengthen its existing supply chain with strategic partners having existing multiple channel access to the ERV or OEM Aqualyte markets – or with qualified outsourced firms.

 

The Company has continued to establish a robust supply chain with strategic partners having existing multiple channel access to markets – or with qualified outsourced firms. We do not have long-term contractual relationships with any of our manufacturers or vendors. There are no subassemblies or components that could not be purchased from alternative suppliers. Purchases to date of raw materials and related services have been on a purchase order basis using non-disclosure agreements.

 

OEM Customers, and Suppliers

 

Using the properties and features of its Aqualyte nanomaterial the Company has proven results in a variety of cross-industry markets. We look to provide Original Equipment Manufacturers (OEMs) with Aqualyte membrane. Then sharing how to use the options and features found in Aqualyte, for the OEM to offer better or even new products in consumer, commercial, and industrial applications having what we believe to be better lifetimes, and efficiencies.

 

We are dependent on third parties to manufacture the key components needed for our nano-structured based materials and of the value-added products made with these materials.

 

We require our suppliers to provide components in a timely manner, and to meet the Company’s quality, quantity and cost requirements or technical specifications with acceptable terms. Certain of the components or the processes of the Company’s suppliers are proprietary. If the Company were ever required to replace any of its suppliers, it should be able to obtain comparable components from alternative suppliers at comparable costs, but this would create delays in production.

 

 
6

Table of Contents

 

Research and Development

 

Expenditures for research, development and engineering of products are expensed as incurred. We incurred research and development costs of $328,480 and $223,425 for the years ended December 31, 2022 and 2021, respectively. We account for proceeds received from government funding for research as a reduction in research and development costs. We recorded proceeds against research and development expenses on the Statements of Operations of $0 and $89,617 for the years ended December 31, 2022 and 2021, respectively.

 

Sales and Marketing Strategies

 

We have secured and continue to discuss relationships with leading industry HVAC manufacturers, HVAC product distributors, energy service companies, and ERV manufacturers outside of North and South America. In addition, we are discussing relationships for use of our ConsERV products in other applications outside of energy recovery ventilation world-wide.

 

The Company is focused on creating alliances with companies having strong, existing channel presence or expertise in the target industries, notably for ConsERV and Aqualyte OEM uses. We are using the data and experience of past sales in a variety of markets, adding newer features and functions, working to increase revenues. We intend to bring industry seasoned talent into the Company at the appropriate time to further drive market development, revenue growth and guide future product feature improvement needs.

 

Competition and Barriers to Entry

 

We believe the efficacy of our value-added products and technology can capture increased market share, thus taking business away from more established firms using older technology. We believe our ConsERV product may become a functional component of newer, more efficient OEM products. A key challenge is to educate decision makers of the benefits derived from products using our materials and processes, and have qualified people and certified products which out-perform other products, diminishing the value proposition of competitive products in the various sales channels. As we continue to grow the base of operational and third-party data this education process will become routine.

 

There are several companies located in the U.S., Canada, Europe, and Asia that have been developing and selling technologies and products in the energy recovery industry as listed below. We will experience significant competition regarding our products because certain competing companies possess greater financial and personnel resources. Future product competitors include, but are not limited to:

 

Products

 

Current and Future Competitors

ConsERV

 

Semco, Greenheck, Venmar, Bry-Air, Fuwei, Ltd, CORE Energy Recovery Solutions, Renewaire, Holtop, Hoval, Klingenberg, Solar Palau, Kraton, Daikin and AirXchange.

 

We believe the combination of our nanomaterial characteristics and growing patent positions form competitive advantages, which may allow us time to execute our business plan. Many of our competitors may experience barriers to entry in these markets primarily related to the lack of similarly performing proprietary materials and processes.

 

 
7

Table of Contents

 

Government Regulation

 

We do not believe the sale, installation or use of our current nano-structured products will be subject to any government regulation, other than perhaps adherence to building codes and water safety regulations. We do not believe that the cost of complying with such codes and regulations, to the extent applicable to our products, will be prohibitive.

 

We do not know the extent to which any existing or new regulations may affect our ability to distribute, install and service any of our products. Once our other products reach the commercialization stage and we begin distributing them to our target markets, federal, state, or local governmental entities may seek to impose regulations.

 

We are also subject to various international, federal, state, and local laws and regulations relating to, among other things, land use, safe working conditions, and environmental regulations regarding handling and disposal of hazardous and potentially hazardous substances and emissions of pollutants into the atmosphere. The process of manufacturing the solutions which are used to produce Aqualyte may expose us to the risk of harmful substances escaping into the environment, resulting in potential injury or loss of life, damage to property and natural resources. Depending on the nature of any claim, our current insurance policies may not adequately reimburse us for costs incurred in settling environmental damage claims and, in some instances, we may not be reimbursed at all. To date, we are not aware of any claims or liabilities under these existing laws and regulations that would materially affect our results of operations or financial condition. The completed products which use the Aqualyte material may have regulatory requirements relating to a variety of local or federal regulatory agencies, however, this type of exposure would be minimal.

 

Employees

 

As of December 31, 2022, we employed 21 full-time employees and one independent contractor. None of the employees are subject to a collective bargaining agreement. We consider our relations with our employees to be good. As of the date of filing the number of employees of the Company has increased to 23.

 

Principal Offices

 

Our principal office is located at 11552 Prosperous Drive, Odessa, FL 33556.

 

ITEM 1A. RISK FACTORS.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the information under this item.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS.

 

Not Applicable.

 

ITEM 2. PROPERTIES.

 

We currently lease 7,200 square feet of combined office and production space located at 11552 Prosperous Drive, Odessa, FL 33556. We lease the site from Ethos Business Ventures, LLC, a limited liability company in which our Chief Executive Officer, Tim Tangredi, has a controlling financial interest (see Item 13, Certain Relationships and Related Transactions and Director Independence).

 

The lease for our corporate headquarters began on March 18, 2005. The lease term will terminate upon 30 days’ written notice from landlord or 90 days written termination from us. The current monthly rent is $4,066 and includes sales tax. We also pay all taxes and utilities as well as most repairs relating to the building. Most of our functions are performed at this site including corporate, marketing, administration, on-going product and nano-structured polymer development and product assembly and shipping. Key polymer synthesis and casting is outsourced and not done at this facility.

 

We do not anticipate investing in real estate or interests in real estate, real estate mortgages, or securities of or interests in persons primarily engaged in real estate activities. We currently have no formal investment policy and do not intend to undertake investments in real estate as a part of our normal operations.

 

 
8

Table of Contents

 

ITEM 3. LEGAL PROCEEDINGS.

 

From time to time, claims are made against us in the ordinary course of our business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties, or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods. There are two items to disclose:

 

 

1.

SOEX

  

On April 24, 2014, the Company entered into a Distribution Agreement (the “Soex Distribution Agreement”) with SOEX (Hong Kong) Industry & Investment Co., Ltd., a Hong Kong corporation (“SOEX”). In 2015 the Company commenced an action (the “Soex Litigation) for the cancellation of the 37,500,000 shares issued to Soex (the “Soex Shares”) in connection with the Soex Securities Purchase Agreement, and for the cancellation of the 3,750,000 shares (the “Zan Shares”) issued to Zan Investment Advisory Limited (“Zan”), In June of 2017 the Litigation was moved to the U.S. District Court for the Middle District of Florida where SOEX instituted a counterclaim (Civil Docket Case #: 8:15-CV-02362-MSS-EAJ. The jury in the October of 2018 trial did not award monetary damages to either party for claims or counterclaims. On October 24, 2018, the Company initiated a third lawsuit against an affiliate of Soex, Zhongshan Trans-Tech New Material Technology Co. Ltd. Zhongshan, China, (“Transtech”), and the Chairperson of the affiliate and Soex, based on new information learned by the Company during the trial. The Company is appealing this award, in which management and the Board feel we will prevail.  In January of 2021 the Company learned the Transtech entity merged with another entity in China, and that entity (“new entity”) sold under fifty percent  off its interests to a large Swiss firm. In August 2021, the Company was notified the judge in the case in the October 2018 event, despite the recommendations of the jury to award no damages or court costs, overturned the ruling and assessed Dais $481,192 in court costs and fees. In early 2022 the remainder of the new entity’s assets to the large Swiss firm.

 

 

2.

Accounts Payable

 

The firms below have pursued legal action against the Company to collect overdue accounts payable sums. The Company is working with each to enter into a settlement plan, or “pay over a period of time” payment plan. To date the Company has one agreement in place with SoftinWay.

 

Company

 

Sum Owned

 

 

Payment Plan

 

Legal Action

 

Old Dominion Freight Line (1)

 

$13,575.95

 

 

No

 

Yes

 

Power Plant Services (2)

 

$85,199.11

 

 

No

 

Yes

 

Softinway (3)

 

$3,350.00

 

 

Yes

 

Yes

 

The O-Ring Store

 

$10,334.00

 

 

No

 

Yes

 

Total

 

$112,459.06

 

 

 

 

 

 

 

Footnotes for Accounts Payable Table

 

 

1.

This action moved towards settlement in December of 2022 and completing in March of 23, 2023. The sum the creditor froze $28,781 of the Company’s funds at the Company’s bank, the parties discussed the matter. The sum owed was agreed to be $17,212 including principle, interest, court costs and legal fees. The agreed sum ($17,212) is in the process of being deducted from the withheld sum at the company's bank. from the withheld $28,781.

 

2.

The sum the creditor froze $4,700 of the Company’s funds at the Company’s bank. Company is exploring post judgement relief options/taking steps to ensure that Secured Noteholders priority is protected.

 

3.

The original balance of approximately $24,165 has been consistently paid down per the repayment agreement.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

 
9

Table of Contents

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES.

 

Our stock is currently trading on the OTC Pink Marketplace operated by OTC Markets Group Inc. under the symbol “DLYT”.

 

Authorized Capital.

 

On March 5, 2015, the Company amended its Certificate of Incorporation to increase the number of authorized shares to 250,000,000, consisting of 240,000,000 shares of common stock and 10,000,000 shares of preferred stock (the “Increase in Authorized Shares”) and to cancel the designated but unissued Series A-D Preferred Stock and create a new series of preferred stock designated as the Class a Preferred Stock (the “Class A Preferred Stock”). There are no shares of Class A Preferred Stock currently issued by the Company.

 

On November 1, 2018, the Company issued ten (10) shares of Class B Redeemable Preferred Stock par value $0.01 per share (“Class B Stock”) having a stated value of $1.50 per share to Tim N. Tangredi, the Company’s Chief Executive Officer, in exchange for $15, pursuant to approval of the Board of Directors of the Company.

 

There are currently (10) shares of Class B Stock of the Company issued and outstanding.

 

On November 2, 2018, the shareholders of the Company approved an increase in the authorized common shares of the company from 240,000,000 shares to 340,000,000 shares. On March 14, 2019, the shareholders approved an increase in authorized common shares from 340,000,000 shares to 1,100,000,000 shares. In July 2019, the shareholders of the Company approved a reverse stock split of the issued and outstanding shares of the Company’s common stock at the ratio ranging from one-for-500 to one-for-2,000. On October 31, 2019, the Company amended its Certificate of Incorporation to reflect a one-for-2,000 reverse stock split of the Company’s common stock. The reverse split was effective December 6, 2019. All share and per share data have been retroactively restated in this annual report and the accompanying financial statements and footnotes to reflect the effects of the reverse split.

 

Approved by the Board on December 31, 2021, and approved on March 23, 2022, by the NY Division of Corporations four new classes Convertible Preferred Stock were created; Series C, D, E, and F. Series C and E are for investors, Series D is for consultants, and Series F is for company employees, board members, and those contractually owned equity previously forfeited gratuitously in January of 2021. Series C and E are issued. Series D is on-hold pending need, and Series F is in process of being issued.

 

Approximate Number of Equity Security Holders

 

As of May 26, 2023, there were approximately 121 shareholders of record of our common stock.

 

Dividends

 

We have not declared or paid any dividends and do not intend to pay any dividends in the foreseeable future to the holders of our common stock. We intend to retain future earnings, if any, for use in the operation and expansion of our business. Any future decision to pay dividends on common stock will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements and other factors our board of directors may deem relevant.

 

Transfer Agent

 

Our transfer agent is Clear Trust Transfer located at 16540 Point Village Drive #210, Lutz, FL 33558, telephone (813) 235-4490.

 

Equity Compensation Plan Information

 

The following table sets forth information regarding our 2000 Incentive Compensation Plan (the “2000 Plan”), 2009 Long-Term Incentive Plan (the “2009 Plan”) and 2015 Stock Incentive Plan (the “2015 Plan”) under which our securities are authorized for issuance as of December 31, 2022:

 

Plan Category

 

(a) Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights

 

 

(b) Weighted Average Exercise Price of Outstanding Options, Warrants and Rights

 

 

 

 

 

 

 

 

Equity compensation plans approved by security holders

 

 

-

 

 

$-

 

 

 
10

Table of Contents

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

There were no unregistered sales of equity securities in 2022 or 2021.

 

Recent Repurchases of Common Stock

 

There were no repurchases of our common stock during 2022 or 2021.

 

ITEM 6. SELECTED FINANCIAL DATA.

 

Not Applicable.

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION.

 

This Management’s Discussion and Analysis of Financial Condition and Results of Operations includes a number of forward-looking statements that reflect Management’s current views with respect to current and future events and financial performance. You can identify these statements by forward-looking words such as “may”, “will”, “expect”, “anticipate”, “believe”, “estimate” and “continue”, or similar words. Those statements include statements regarding the intent, belief or current expectations of the management team as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.

 

Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission. Important factors currently known to us could cause actual results to differ materially from those in forward-looking statements. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time. We believe that its assumptions are based upon reasonable data derived from and known about our business and operations and the business and operations of the Company. No assurances are made that actual results of operations or the results of our future activities will not differ materially from its assumptions. Factors that could cause differences include, but are not limited to, expected market demand for the Company’s services, fluctuations in pricing for materials, and competition.

 

Unless otherwise indicated or the context requires otherwise, the words “we”, “us”, “our”, the “Company” or “our Company” refer to Dais Corporation, a New York corporation, and its subsidiaries.

 

OVERVIEW

 

Overview

 

Dais Corporation (“Dais”, “us,” “we,”, the “Company”) is a nanomaterial technology company developing and commercializing products using the nanomaterial called Aqualyte. The first commercial product is the Aqualyte nanomaterial itself. It is useful in managing moisture and key gases in a variety of cross-industry products. The second commercial product is called ConsERV, a fixed plate energy recovery ventilator which is useful in meeting building indoor fresh air requirements while saving energy and lowering emissions for most forms of heating, ventilation, and air conditioning (HVAC) equipment. We continue to develop other Aqualyte uses in cross-industry applications, HVAC/Refrigeration, energy, etc. One area of focused attention has been development work on a variant of Aqualyte targeting surface treatments to potentially create a protective layer designed to inactivate human coronaviruses.

 

 
11

Table of Contents

 

RESULTS OF OPERATIONS

 

Year Ended December 31, 2022 as compared with December 31, 2021

 

The following table sets forth, for the periods indicated, certain data derived from our Statements of Operations:

 

 

 

For the Years Ended

December 31,

 

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

REVENUE

 

 

 

 

 

 

Sales

 

$1,077,058

 

 

$372,506

 

Royalty and license fees

 

 

50,000

 

 

 

50,000

 

 

 

 

1,127,058

 

 

 

422,506

 

 

 

 

 

 

 

 

 

 

COST OF GOODS SOLD

 

 

977,518

 

 

 

267,837

 

 

 

 

 

 

 

 

 

 

GROSS MARGIN

 

 

149,540

 

 

 

154,669

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

Research and development, net of government grant proceeds of $0 and $89,617 for the years ended December 31, 2022 and 2021, respectively

 

 

328,480

 

 

 

133,808

 

Selling, general and administrative

 

 

1,668,389

 

 

 

1,958,560

 

TOTAL OPERATING EXPENSES

 

 

1,996,869

 

 

 

2,092,368

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(1,847,329 )

 

 

(1,937,699 )

 

 

 

 

 

 

 

 

 

OTHER INCOME (EXPENSE)

 

 

 

 

 

 

 

 

Interest expense

 

 

(2,728,360 )

 

 

(2,065,593 )

Loss on legal judgement

 

 

-

 

 

 

(382,664 )

Forgiveness of debt income

 

 

124,126

 

 

 

146,685

 

Change in fair value of derivative

 

 

-

 

 

 

2,241,678

 

Gain on extinguishment of debt

 

 

-

 

 

 

1,148,554

 

TOTAL OTHER INCOME (EXPENSE), NET

 

 

(2,604,234 )

 

 

1,088,660

 

 

 

 

 

 

 

 

 

 

NET LOSS

 

$(4,451,563 )

 

$(849,039 )

 

 

 

 

 

 

 

 

 

NET LOSS PER COMMON SHARE, BASIC AND DILUTED

 

$(0.43 )

 

$(0.15 )

 

 

 

 

 

 

 

 

 

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED

 

 

10,448,440

 

 

 

5,734,795

 

 

Revenue

 

We generate our revenues primarily from the sale of our ConsERV cores and systems, and our Aqualyte membrane. Product sales were $1,077,058 and $372,506 for the years ended December 31, 2022 and 2021, respectively, an increase of $704,552 or 189%. This increase in product sales was primarily driven by an increase in sales of our ConsERV product line, offset by a decrease in Aqualyte only OEM sales.

 

Revenues from royalty and license fees were $50,000 and $50,000 for the years ended December 31, 2022 and 2021, respectively.

 

 
12

Table of Contents

 

Cost of Sales

 

Our cost of sales consists primarily of materials (including freight), direct labor, and outsourced manufacturing expenses incurred to produce our ConsERV cores and systems and Aqualyte membrane. Cost of goods sold were $977,518 and $267,837 for the years ended December 31, 2022 and 2021, respectively, an increase of $709,681 or 265%. The increased cost is primarily due to increased product sales, labor costs, materials, and normal variances in costs between our product lines..

 

Supply Chain (Availability and Increased prices) and Tightening labor market (money and people)

 

Current world-wide supply chain issues are impacting many industries, including those of the Company. The lead time for materials and components is increasing, resulting in longer delivery dates. Management is working with existing partners to identify multiple sources of materials and components so as not to rely heavily on one or two suppliers.

 

Increasing crude oil prices is influencing the cost of resins, plastics and fuel. Shipping and trucking costs have increased while capacity has contracted. These issues are creating increased costs across industries and Management is evaluating its’ pricing and lead times regularly.

 

The labor market is having an impact across industries as competition for workers is increasing. Management is working to anticipate workforce needs and planning accordingly.

 

The Company is dependent on third parties to manufacture the key components needed for its nanostructured materials and some portions of the value-added products made with these materials. Accordingly, a suppliers’ failure to supply components in a timely manner, or to supply components that meet the Company’s quality, quantity and cost requirements or technical specifications, or the inability to obtain alternative sources of these components on a timely basis or on acceptable terms, would create delays in production of the Company’s products and/or increase its unit costs of production. Certain of the components or the processes of the Company’s suppliers are proprietary. If the Company was ever required to replace any of its suppliers, it should be able to obtain comparable components from alternative suppliers at comparable costs, but this would create a delay in production and may briefly affect the Company’s operations.

 

Covid-19 World-wide Pandemic

 

Management continues to monitor the after effects the pandemic across the globe. As creative solutions to protect us from future infections the Company hasdeveloped what we believe using our technology is a uniquely positioned product designed to provide a positive health supporting solution to the existing or similar possible future pandemics (virus or bacteria).

 

We believe the integration of this newer solution, once development is complete, fits well to support even higher emphasis on the need for high efficiency  ventilation which itself appears to management to be a lesson learned from the COVID19 pandemic Management is developing and plans to soon execute crease a program to focus on the integration of high efficiency ventilation and a industry-setting use of the company’s known features/benefits using its platform of nanomaterial. The plan is being formulated, will use, at a minimum, the existing sales channels to create what we believe is yet another benefit which finds ConsERV the best ventilation product in most instances.

  

Climate Change and Carbon Reduction

 

Countries and corporations around the world are adopting aggressive plans to achieve newly established Carbon Neutral goals by 2030 and 2050. This worldwide effort is attracting attention to innovative technologies which reduce carbon emissions. Management is confident in the successful track record of current products, with a history of increasing the efficiency of HVAC systems and reducing CO2 emissions should drive increased business activity.

 

Dais is actively involved in preparing its existing and planned products and those products we are working on with partners, to fully participate in the decarbonization of business.

 

The Company’s goal is to incorporate novel features of its nanomaterial platform to enable evolutionary or industry changing products. This is accomplished by replacing energy consuming, emissions creating product components (pumps, motors, gases, ‘forever chemical’ laden items, etc.) with products made using an architecture best managing the features of the Company’s platform of nanomaterial having higher efficiencies, lower emissions, longer life, fewer breakdown, gentle on the environment, good for your health and productivity.

 

 
13

Table of Contents

 

Research and Development

 

Expenditures for research, development and engineering of products are expensed as incurred. We incurred research and development costs of $328,480 and $223,425 for the years ended December 31, 2022 and 2021, respectively, an increase of $105,055 or 47%. We account for proceeds received from government funding for research as a reduction in research and development costs. We recorded proceeds against research and development expenses on the Statements of Operations of $0 and $89,617 for the years ended December 31, 2022 and 2021, respectively, a decrease of $89,617 or 100%. The decrease in proceeds from government funding was due to the completion of U.S. Army Corps of Engineers, $1,000,000, Phase II Small Business Innovation Research (SBIR) award ending in the third quarter of 2021. 

 

Selling, General and Administrative

 

Our selling, general and administrative expenses consist primarily of payroll and related benefits, share-based compensation, professional fees, marketing and channel support costs, and other infrastructure costs such as insurance, information technology and occupancy expenses. Selling, general and administrative expenses were $1,668,389 and $1,958,560 for the years ended December 31, 2022 and 2021, respectively, a decrease of $290,171 or 15%.

 

Our selling, general and administrative expenses may fluctuate due to a variety of factors, including, but not limited to:

 

 

●

Additional expenses because of being an SEC reporting company including, but not limited to, director and officer insurance, director fees, SEC compliance expenses, transfer agent fees, additional staffing, professional fees, and similar expenses;

 

 

 

 

●

Additional infrastructure needed to support the expanded commercialization of our ConsERV products and/or new product applications of our polymer technology for, among other things, administrative personnel, physical space, marketing and channel support and information technology; and

 

 

 

 

●

The issuance and recognition of expense related to fair value of new share-based awards, which is based on various assumptions including, among other things, the volatility of our stock price.

 

The 15% decrease in selling general and administrative expenses in the year ended December 31, 2022 compared to the same period in 2021 resulted primarily from a decrease in stock-based compensation offset by increased payroll costs.

 

Other Income (Expense)

 

Interest expense for the year ended December 31, 2022 was $2,728,360 compared to an expense of $2,065,593 for the year ended December 31, 2021. Change in fair value of derivative was $0 in 2022 compared to a gain of $2,241,678 in 2021 and there was a decrease in gain on extinguishing debt from $1,148,554 in 2021 to $0 in 2022. The gain on extinguishing debt in 2021 was due to the settlement of our convertible notes payable.

 

Net Loss

 

Net loss for the year ended December 31, 2022 was $4,451,563 compared to a net loss of $849,039 for the year ended December 31, 2021. The increased net loss in 2022 was primarily due to the change in fair value of derivatives and the settlement of our convertible notes payable in 2021.

 

 
14

Table of Contents

 

Liquidity and Capital Resources

 

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. For the year ended December 31, 2022, the Company generated a net loss of $4,451,563 and has incurred significant losses since inception. As of December 31, 2022, the Company has an accumulated deficit of $62,274,665, total stockholders’ deficit of $12,430,988, negative working capital of $12,468,216 and cash and cash equivalents of $27,412. The Company used $1,451,315 and $1,283,772 of cash for operations during the years ended December 31, 2022, and 2021, respectively, which was funded primarily by proceeds from loans from related parties and others. There is no assurance that any such financing will be available in the future. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company is currently pursuing the following sources of short and long-term working capital:

 

 

1.

The Company guided by its Financial Advisors is actively working with targeted third parties who have or are interested in licensing, purchasing the rights to, or establishing a joint venture to commercialize applications of the Company’s technology;

 

 

 

 

2.

The Company continues to seek capital from key strategic and/or government (grant) related sources. These sources may, pursuant to any agreements that may be developed in conjunction with such funding, assist in the product definition and design, roll-out, and channel penetration of products;

 

 

 

 

3.

The Company is actively working with newer investors, private equity companies, purchase order financing parties, and its existing debt holders to restructure its existing debt and obtain short and long-term working and growth capital; and,

 

 

 

 

4.

The Company may license or sell an asset to fund its continued growth as it is clear to management the market for the Company’s  product innovations has changed in a positive way as demonstrated by the interest the Company’s nano-material and applications in certain markets.

 

Management believes:

 

 

1.

The Company’s ability to solve continuing supply chain issues and raise sustainable growth capital will dictate future revenue and cash-flow for the Company. The quicker these issues are resolved we believe the faster the Company can participate in the market’s uptick momentum and follow the projected growth curve.  These issues place heavy pressure on management to progress in key business areas being impacted.   Continued supply chain impacts has roots in the funding challenges. The use of funds from affordable growth capital to resolve inventory levels of hard to acquire parts could be achieved within one quarter. Raising affordable capital is tied to addressing/fixing convertible debt transactions (recently found to be ‘criminally usurious - (Adar v. Geneysy, LLC) used in the past to grow the Company with a plan to replace this convertible debt with lower cost funds. The Company has made progress yet still faces a worldwide public market in turmoil since February of 2022. In the intertest of expediting this situation the Company is seeking affordable public, and non-public, growth resources, with Board approval, is seeking to monetize one asset via a license/supply agreement.  Such a plan (monetize an asset) will require approval by the Company’s Senior Secured Noteholder.

 

 

 

 

2.

The Senior Secured Note Holder has advised Management it is exploring its options to resolve the long standing unpaid – and growing debt by the Company.

 

 

 

 

3.

Ventilation is regularly recommended as one of the solutions to Covid related mitigation and the market awareness for the ConsERV product(s) is increasing and lead activity is encouraging.

 

 

 

 

4.

We believe our current cash position and our projected ability to obtain additional sources of growth capital, and to generate sustainable cash flow from operations and investments into 2023 is improving yet remains challenged.

 

We believe the Company’s prospects to secure growth funding are good. The company has shown solid progress over the last three quarters, removed a serious impediment to growth by completing a ‘debt to equity’ program where the convertible noteholders debt positions were converted into equity (common stock and warrants). The company introduced a popular new line of our ConsERV equipment  having improved performance and pricing to a growing independent sales channel through-out  North America. We reached agreement (now moving to contract stage) in late 4Q 2022 between the company and its Senior Secured Note Holder (having deep rights with the assets of the Company which are pledged as security for repayment of the Note). The company is continuing to develop the basis of a long term business relationship  with a well-known, multi-national corporation interested in using the Company’s products for its own and third-party use. 

 

There are no assurances we will be able to obtain the financing and planned product development commercialization. Accordingly, we may not have the ability to continue as a going concern. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should we be unable to continue as a going concern.

 

 
15

Table of Contents

  

Statements of Cash Flows

 

Cash and cash equivalents as of December 31, 2022 were $27,412 compared to $773,423 as of December 31, 2021. Cash is primarily used to fund our working capital requirements.

 

Net cash used in operating activities was $1,451,315and $1,283,772  for the years ended December 31, 2022 and 2021, respectively. The increase in net cash used in operations was primarily due to a decrease in cash from net working capital accounts partially offset by a decrease in net loss (after adjusting for non-cash items). For the year ended December 31, 2022, net loss (after adjusting for non-cash items) was $2,874,557. Accounts receivable, inventory and other assets together increased by $422,430. Accounts payable, accrued liabilities, customer deposits and deferred revenue increased in total by $1,845,672. For the year ended December 31, 2021, net loss (after adjusting for non-cash items) was $3,162,483. Accounts receivable, inventory and other assets together decreased by $53,624. Accounts payable, accrued liabilities, customer deposits and deferred revenue increased in total by $1,932,335.

 

Net cash used by investing activities was $45,148 and $29,758 for the year ended December 31, 2022 compared to the same period in 2021.The increase was driven primarily by equipment purchases in 2022.

 

Net cash provided by financing activities was $750,452 and $2,050,437 for the years ended December 31, 2022 and 2021. respectively. The decrease resulted from decreased proceeds from notes payable offset by an increase in proceeds from notes payable to related parties.

 

Material Financing Transactions

 

Debt to Equity Exchange Program

 

In the period from June 2017 through the end of December 2019, the Company entered eight Convertible Note Holder agreements with eight Note Holders totaling, with all fees, interest, and principal, $2,008,812 as of December 31, 2020. The notes were not considered to be in default and were being renegotiated at March 31, 2021. Subsequently, as of May 31, 2021, each Convertible Noteholder received their fees, interest, and principal totaling $2,107,414 in shares of Common stock of the Company (at $0.030 per share) with 50% warrant coverage (1 year cash warrant with a strike price of 0.30). All documents were executed by June 30, 2021, with all equity/warrants issued by July 31, 2021. The Company issued 7,036,668 Common shares, and 3,576,733 Warrant shares in this transaction. All unexercised warrants expired as of May 15, 2022 per the terms and conditions of the Warrant document.

 

2022 Convertible Notes

 

On December 12, 2022, the Company entered a convertible promissory note in the amount of $40,000. The note matures on the earlier of June 12, 2023 or 5 days after demand and bears interest at 10% per year. The note is convertible into shares of common stock at a fixed conversion price of $0.30 per share.

 

On November 4, 2022, the Company entered a convertible promissory note in the amount of $25,000. The note matures on the earlier of May 4, 2023 or 5 days after demand and bears interest at 10% per year. The note is convertible into shares of common stock at a fixed conversion price of $0.30 per share.

 

On September 7, 2022, the Company entered a convertible promissory note in the amount of $100,000. The note matures on September 7, 2023 and bears interest at 8% per year. In connection with this note, the Company has issued a warrant to purchase 1,000,000 shares of common stock to the lender. The warrant has an exercise price of $0.30 per share and expires on September 7, 2027. The relative fair value of the warrant was $59,998, determined using the Black Scholes Model with the following assumptions: (1) risk free interest rate of 3.37%; (2) dividend yield of 0%; (3) volatility factor of the expected market price of the Company’s common stock of 360%; and (4) an expected life of 5 years. The note is convertible into shares of common stock at a fixed conversion price of $0.10 per share. The company has recorded a beneficial conversion feature of $40,002. Amortization of discount was $31,781 for the year ended December 31, 2022.

 

On August 20, 2022, the Company entered a convertible promissory note in the amount of $49,850. The note matures on the earlier of February 20, 2023 or 10 days after demand and bears interest at 8% per year. The note is convertible into shares of common stock at a fixed conversion price of $0.30 per share.

 

On June 15, 2022, the Company entered two convertible promissory notes aggregating $300,000. The notes mature on the earlier of December 15, 2022 or 10 days after demand and bear interest at 8% per year. The Company received proceeds of $300,000. The notes are convertible into shares of common stock at a fixed conversion price of $0.30 per share. The Company has recorded debt discount of $200,000, related to the beneficial conversion feature of the notes. The discount will be amortized to interest expense over the six-month term of the notes, and $200,000 was amortized during the year ended December 31, 2022, respectively.

 

 
16

Table of Contents

 

2021 Convertible Notes

 

On September 20, 2021, the Company entered a convertible promissory note with GS Capital Partners, LLC. The note matured on September 20, 2022 and bears interest at 8% per year. The Company received proceeds of $197,000, after deduction of $20,000 of original issue discount and $3,000 of costs. In connection with this note, the Company has issued a warrant to purchase 1,466,666 shares of common stock to the lender. The warrant has an exercise price of $0.15 per share and expires on September 21, 2026. The relative fair value of the warrant was $110,000, determined using the Black Scholes Model with the following assumptions: (1) risk free interest rate of 0.84%; (2) dividend yield of 0%; (3) volatility factor of the expected market price of the Company’s common stock of 389%; and (4) an expected life of 5 years. The note is convertible into shares of common stock at a fixed conversion price of $0.10 per share. The company has recorded a beneficial conversion feature of $90,000. Amortization of discount and costs was $160,071 and $62,929 for the years ended December 31, 2022 and 2021, respectively. The note matured on September 20, 2022. The lender has not declared a default as both parties are actively discussing a mutually beneficial path forward.  It is expected an agreement will be reached in the fourth quarter of 2022.

 

During the fourth quarter of 2021, the Company entered twenty convertible promissory notes with various holders aggregating $1,412,000. The notes mature one year from issuance and bear interest at 8% per year. The Company received proceeds of $1,287,000, after deduction of $117,000 of original issue discount and $8,000 of costs. In connection with the notes, the Company has issued warrants to purchase 10,463,332 shares of common stock to the lenders. The warrants have an exercise price of $0.15 per share and expire five years from the date of issuance. The relative fair value of the warrants was $1,366,127, determined using the Black Scholes Model with the following assumptions: (1) risk free interest rate of 0.84% - 1.33%; (2) dividend yield of 0%; (3) volatility factor of the expected market price of the Company’s common stock of 386% - 389%; and (4) an expected life of 5 years. The notes are convertible into shares of common stock at a fixed conversion price of $0.10 per share. A total of $1,412,000 has been recorded as debt discount, and 8,000 has been recorded as deferred debt costs. The discount and costs will be amortized to interest expense over the term of the notes Amortization of discount and costs was $1,236,089 and $142,233 for the years ended December 31, 2022 and 2021, respectively.

 

COVID-19 Disclosure

 

The Company’s operations continue to be impacted by the aftermath of the outbreak of the coronavirus disease (COVID-19) which was declared a pandemic by the World Health Organization in March 2020. The ongoing disruption relating to the availability of certain components and parts is impacting lead times causing delays in order fulfillment. Further the lasting impacts resulted in an adverse impact on the Company’s operations, as ur third-party manufacturers, and distributors work through the lasting impacts of shortages in the supply and availability of component and parts. Awareness of research relating to the need for increased ventilation, which aides in the fight against viruses and other allergens in our indoor spaces, is changing buying habits. This change in attitudes is driving an increase in the markets for our nano-based products.

 

Economy and Inflation

 

Except as disclosed herein, we have not experienced any significant cancellation of orders due to the downturn in the economy. Our management believes that inflation will have an effect on our cost of goods and shipping, however sales inquiries continue to be strong through 2022.

 

Contractual Obligations

 

We do not have any liabilities related to long-term contractual obligations as of December 31, 2022.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues, and results of operations, liquidity, or capital expenditures.

 

 
17

Table of Contents

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

The preparation of the accompanying financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires us to make judgments, assumptions and estimates that affect the amounts reported in the accompanying financial statements and the accompanying notes. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. When making these estimates and assumptions, we consider our historical experience, our knowledge of economic and market factors and various other factors that we believe to be reasonable under the circumstances. Actual results could differ from these estimates. Management has discussed the selection of critical accounting policies and estimates with our Board of Directors, and the Board of Directors has reviewed our disclosure relating to critical accounting policies and estimates in this annual report on Form 10-K. The following critical accounting policies are significantly affected by judgments, assumptions and estimates used in the preparation of the financial statements:

 

Revenue Recognition

 

Generally, we recognize revenue for products upon shipment to customers, provided no significant obligations remain and collection is probable.

 

In certain instances, our ConsERV system product may carry a limited warranty of up to two years for all parts contained therein except for the energy recovery ventilator core produced and sold by us. The distributor of the ConsERV system may carry a limited warranty of up to ten years. The limited warranty includes replacement of defective parts for the ConsERV system and includes workmanship and material failure for the ConsERV core. We have recorded an accrual of $91,531 for future warranty expenses on December 31, 2022, which is included in accrued expenses, other.

 

Revenue derived from the sale of licenses is deferred and recognized as license fee revenue on a straight-line basis over the life of the license, or until the license arrangement is terminated. We recognized license fee revenue of $50,000 and $50,000 for the years ended December 31, 2022 and 2021, respectively. Royalties are recognized as earned. We did not recognize any revenue from royalties for the years ended December 31, 2022 and 2021.

 

The Company has adopted the new revenue recognition guidelines in accordance with ASC 606, Revenue from Contracts with Customers (ASC 606), commencing from the period under this report. The Company analyzes its contracts to assess that they are within the scope and in accordance with ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, whether for goods and services or licensing, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company acts as a principal in its revenue transactions as the Company is the primary obligor in the transactions. Generally, the Company recognizes revenue for its products upon shipment to customers, provided no significant obligations remain and collection is probable.

 

Accounts Receivable

 

Accounts receivable consist primarily of receivables from the sale of our ERV products and Aqualyte membrane. We regularly review accounts receivables for any bad debts based on an analysis of our collection experience, customer credit worthiness and current economic trends. After all attempts to collect a receivable have failed, the receivable is written off against the allowance. Based on management’s review of accounts receivable, an allowance for doubtful accounts of $0 and $0 has been recorded on December 31, 2022 and 2021, respectively.

 

Impairment of Long-Lived and Intangible Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. We periodically evaluate whether events and circumstances have occurred that indicate possible impairment. When impairment indicators exist, we use market quotes, if available, or an estimate of the future undiscounted net cash flows of the related asset or asset group over the remaining life in measuring whether the asset values are recoverable. We did not recognize impairment on its long-lived assets during the years ended December 31, 2022 or 2021.

 

Identified intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Our existing intangible assets consist solely of patents. Patents are amortized over their estimated useful or economic lives of 17 years. Patent amortization expense was $19,989and $18,885 for the years ended December 31, 2022 and 2021, respectively. Based on current capitalized costs, total patent amortization expense is estimated to be approximately $20,000 per year for the next five years and thereafter.

 

Stock-Based Compensation

 

We recognize all share-based payments to employees, including grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period) or immediately if the share-based payments vest immediately.

 

 
18

Table of Contents

 

There were no stock options issued during the year ended December 31, 2022 and 2021.

 

Derivative Financial Instruments

 

We do not use derivative instruments to hedge exposure to cash flow, market, or foreign currency risk. Terms of convertible promissory note instruments are reviewed to determine whether they contain embedded derivative instruments that are required under ASC 815 “Derivative and Hedging” (ASC 815) to be accounted for separately from the host contract and recorded on the balance sheet at fair value. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.

 

Freestanding warrants issued by us in connection with the issuance or sale of debt and equity instruments are considered to be derivative instruments and are evaluated and accounted for in accordance with the provisions of ASC 815. Pursuant to ASC 815, an evaluation of specifically identified conditions is made to determine whether fair value of warrants issued is required to be classified as equity or as a derivative liability.

 

Income Taxes

 

Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes resulting from temporary differences. Such temporary differences result from differences in the carrying value of assets and liabilities for tax and financial reporting purposes. The deferred tax assets and liabilities represent the future tax consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

 

We identify and evaluate uncertain tax positions, if any, and recognize the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. We have not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, we would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s 2018-2021 tax years remain open and subject to examination by the Internal Revenue Service.

 

RECENT ACCOUNTING PRONOUNCEMENTS

 

For a description of recent accounting standards, including the expected dates of adoption and estimated effects, if any, on our financial statements, see Part II, Item 8 Note 3 Significant Accounting Policies: Recent Accounting Pronouncements.

 

 
19

Table of Contents

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not Applicable

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

Our financial statements and the related notes begin on Page F-1 which are included in this Annual Report on Form 10-K.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

 

None

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the Exchange Act)). Management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2022. Management’s assessment was based on criteria set forth in Internal Control Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

 

Limitations on the Effectiveness of Controls

 

Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Based on their evaluation as of the end of the period covered by this report, management concluded that our disclosure controls and procedures were not effective to provide reasonable assurance that the objectives of our disclosure control system were met as a result of limited resources, and a lack of segregation of duties.

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Internal control over financial reporting is a process, including policies and procedures, designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles. Based on the results of this assessment, our management concluded that the Company’s existing internal controls over financial reporting were not effective as defined in Rule 12a-15(f) under the Exchange act as of December 31, 2022 as a result of limited resources, and a lack of segregation of duties.

 

Auditor’s Report on Internal Control over Financial Reporting

 

This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this Annual Report.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting identified in connection with our evaluation that occurred during the quarter ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

ITEM 9B. OTHER INFORMATION.

 

None.

 

 
20

Table of Contents

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

The following table sets forth the names and ages of all our directors and executive officers as of the date of this Annual Report. Also, provided herein is a brief description of the business experience of each director and executive officer during the past five years and an indication of directorships held by each director in other companies subject to the reporting requirements under the Federal securities laws. All the directors will serve until the next annual meeting of shareholders and until their successors are elected and qualified, or until their earlier death, retirement, resignation, or removal. There are no arrangements or understandings between any director or executive officer and any other person pursuant to which the director or executive officer was selected.

 

Name

 

Age

 

Position

Tim N. Tangredi

 

67

 

President, Chief Executive Officer and Chairman of the Board of Directors

Brian C. Johnson

 

50

 

Chief Technology Officer

Rasool Nasr Isfahani

 

37

 

Chief Innovation Officer

Kailey M. Humpel

 

26

 

Office Manager, Board Secretary

Robert W. Schwartz

 

78

 

Director

Ira William McCollum, Jr.

 

78

 

Director

Eliza Wang

 

45

 

Director

 

Directors and Executive Officers

 

The following are our key executive officers:

 

Tim Tangredi has been our Chief Executive Officer since 1996. Mr. Tangredi joined us part time in 1996 and was appointed a member of our board of directors in 1998. In 1999 and 2000, respectively, Mr. Tangredi initiated and executed the strategic purchases of assets of other companies, created serval joint ventures, and sold company assets in his tenure with the Company. From 1979 to 1990, Mr. Tangredi worked for AT&T working in technical marketing, network operations, and project management. From 1991 – 1998 Tangredi started/purchased/sold two companies. Mr. Tangredi earned his BS from Siena College and MBA from Rensselaer Polytechnic Institute. He is a founder and member of the board of directors of Aegis Biosciences, LLC (“Aegis”). Aegis, created in 1995, is a licensee of our nano-structured intellectual property and materials in the biomedical and healthcare fields.

 

Brian Johnson is our Chief Technology Officer and joined us in 1999. Mr. Johnson was the lead engineer responsible for developing our successful ConsERV product line and has served as Principal Investigator on multiple development efforts involving NanoClear and NanoAir. He holds patents in both the U.S. and China and brings 20 years of advanced product development experience and knowledge of every aspect of Dais’ nanotechnology. Mr. Johnson earned degrees in Mechanical Engineering (Thermal Science emphasis) from the University of Florida (BSME 1995, MSME 1997).

 

Rasool Isfahani, PhD. is our Chief Innovation Officer.  Dr. Isfahani joined Dais in 2015 after earning his doctorate degree from University of Florida in Mechanical Engineering. Dr. Isfahani is responsible for bringing new revenue generating ideas from ‘concept to product”, and the continued innovation of the Aqualyte material platform. He has more than 12 years’ experience in membrane-based technologies resulting with 20+ reviewed journal/conference articles and patents.  

Kailey Humpel has been added as a secretary for the Company by the Board of Directors during its December 17, 2021 meeting.

 

The following are our Board of Directors:

 

Eliza Xuan Wang joined our board of directors on April 1, 2015. Ms. Wang has been the Managing Attorney of The Meridian Law, a Professional Law Corporation, since 2009. Her legal practice includes venture capital, general civil and commercial litigation, and immigration matters. Ms. Wang is licensed to practice law in the states of California and New York. She has a Bachelor of Law degree from China University of Political Science and Law (Beijing, China) and L.L.M. degree from Hastings College of The Law, University of California. Ms. Wang’s expertise in commercial and legal matters in both the United States and China will be an asset to us as we conduct further business in China.

 

Robert W. Schwartz was appointed to our board of directors in 2001. Mr. Schwartz founded the Schwartz-Heslin Group (“SHG”) in 1985 and serves as its chairman. Mr. Schwartz specializes in corporate planning, finance, and development. Prior to starting SHG, he was a founder, President and Chief Executive Officer of a venture-funded high-tech telecommunications company (Windsource, Inc.). In addition, he was the President and Chief Operating Officer of an AMEX listed company (Coradian Corporation). He was also the Chief Financial Officer of a major manufacturer of outdoor power equipment (Troy Built Products). His earlier experience was with KPMG and IBM as a management consultant. Mr. Schwartz received a Bachelor of Science from Cornell University and attended graduate courses at the University of New York at Albany. He currently serves on the boards of five corporations, including ours. Mr. Schwartz’s experience in financial planning and reporting provides assistance to us in these areas and he is considered to be a financial expert to us.

 

Ira William McCollum, Jr. joined our board of directors on March 25, 2013. In 2011, Mr. McCollum joined as a partner in Denton’s Public Policy and Regulation practice in 2012. He joined the firm following his term as the 36th attorney general of the state of Florida. Mr. McCollum served as attorney general from 2007 to 2011. Prior to becoming the Florida Attorney General in 2007, Mr. McCollum was a partner with Baker & Hostetler’s Government Policy practice from 2001 to 2007. Between 1981 and 2001, Mr. McCollum was a Member of the U.S. House of Representatives representing Florida’s 8th District where he served on the Judiciary, Banking and Financial Services and Intelligence Committees. He also held a number of leadership positions, including Chairman of the Judiciary Subcommittee on Crime, Vice Chairman for six years at the Banking and Financial Services Committee, ranking Member of the subcommittee overseeing the Federal Reserve, and Vice Chairman of the House of Republican Conference for three terms (one of eight House GOP leadership positions). Mr. McCollum’s expertise in federal and state government and regulations is an asset to the board.

 

 
21

Table of Contents

 

The Board members serve for the latter of a period of one year or until the next annual meeting of Company’s shareholders.

 

Significant Employees

 

John Walsh is the Company’s General Manager. Mr. Walsh started as General Manager in June of 2021. John is responsible for the operational effectiveness of the Dais team and business. John’s prior positions included counseling CEO’s and entrepreneurs in the development of internal systems and business growth strategies creating high powered teams bringing new, innovative, and disruptive technologies to market. John joined Dais after a long and successful economic development career in the Tampa Bay region of Florida.

 

Proceedings

 

During the last ten years, none of our officers, directors, promoters, or control persons have been involved in any legal proceedings as described in Item 401(f) of Regulation S-K.

 

Director Independence

 

We have determined that our board of directors currently has two members who qualify as “independent” as the term is used in Item 407 of Regulation S-K as promulgated by the SEC and as that term is defined under NASDAQ Rule 4200(a)(15). As of the date of this report, Robert W. Schwartz and Eliza Wang are our independent directors. Based on information solicited from Mr. Schwartz, and Ms. Wang, none of them has a material relationship with us and is independent within the meaning of such rules.

 

Board Meetings and Committees; Annual Meeting Attendance

 

Although we intend to establish an audit committee and compensation committee, our board of directors has not adopted any committees to the board of directors. Our board of directors held six formal meetings during the most recently completed fiscal year. Other proceedings of the board of directors were conducted by resolutions consented to in writing by all the directors and filed with the minutes of the proceedings of the directors. Such resolutions consented to in writing by the directors entitled to vote on that resolution at a meeting of the directors are, according to the corporate laws of the State of New York and our bylaws, as valid and effective as if they had been passed at a meeting of the directors duly called and held.

 

At annual meetings of shareholders, Directors are elected by the holders of common stock to succeed those directors whose terms are expiring. Directors will be elected annually and will serve until successors are duly elected and qualified or until a director’s earlier death, resignation, or removal. Our bylaws provide that the authorized number of directors may be changed by action of most of the board of directors or by a vote of the shareholders of our Company. Vacancies in our board of directors may be filled by a majority vote of the board of directors with such a newly appointed director to serve until the next annual meeting of shareholders, unless sooner removed or replaced. We currently do not have a policy regarding the attendance of board members at the annual meeting of shareholders.

 

Code of Ethics

 

We have adopted a code of ethics that applies to our officers, directors, and employees in accordance with applicable federal securities laws. We have filed a copy of our code of ethics as an exhibit to our Annual Report on Form 10-K as filed on March 31, 2009. This document may be reviewed by accessing our public filings at the SEC’s web site at www.sec.gov. In addition, a copy of the code of ethics will be provided without charge upon request to us. We intend to disclose any amendments to or waivers of certain provisions of our code of ethics in a Current Report on Form 8-K.

 

 
22

Table of Contents

 

Compliance with Section 16(a) of the Exchange Act

 

Section 16(a) of the Exchange Act requires our executive officers and directors, and persons who own more than 10% of any publicly traded class of our equity securities, to file reports of ownership and changes in ownership of our equity securities with the SEC. Officers, directors, and greater than ten percent stockholders are required by SEC regulation to furnish the Company with copies of all Section 16(a) forms that they file. Based solely on the reports received and on the representations of the reporting persons, we believe that these persons have complied with all applicable filing requirements of Section 16(a) of the Exchange Act during fiscal year 2018.

 

ITEM 11. EXECUTIVE COMPENSATION

 

Executive Officer Compensation

 

The Summary Compensation Table below sets forth the total compensation paid or earned for the fiscal years ended December 31, 2022 and 2021 for: (i) each individual serving as our chief executive officer (“ CEO ”) or acting in a similar capacity during any part of fiscal 2022; and (ii) the other two most highly paid executive officers (collectively, the “Named Executive Officers”) who were serving as executive officers at the end of fiscal 2022.

 

 

 

Year

 

Salary ($)

 

 

Bonus ($)

 

 

Option

Awards

 

 

All Other

Compensation

 

 

Total ($)

 

Name and principal position (a)

 

(b)

 

(c)

 

 

(d)

 

 

($)(1)(f)

 

 

($)(i)

 

 

(j)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tim N. Tangredi (2)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Chief Executive Officer, President,

 

2022

 

$166,367

 

 

 

 

 

 

 

 

36,674

 

 

$203,041

 

and Chairman of the Board of Directors

 

2021

 

$149,359

 

 

$-

 

 

$

 

 

$36,674

 

 

$186,033

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Brian Johnson

 

2022

 

$140,644

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$140,644

 

Chief Technology Officer

 

2021

 

$135,000

 

 

$-

 

 

$

 

 

$-

 

 

$135,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rasool Nasr Isfahani

 

2022

 

$141,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$141,000

 

Chief Innovation Officer

 

2021

 

$115,360

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$115,360

 

_____________ 

(1)

The amounts included in these columns are the aggregate dollar amounts of the grant date fair value of option awards granted in the indicated year as adjusted to disregard the effects of any estimate of forfeitures related to service-based vesting, in accordance with Accounting Standards Codification 718, Compensation-Stock Compensation, for the fiscal years ended December 31, 2022 and 2021. See Part II, Item 8, Financial Statements and Supplementary Data - Note 3 for information on the valuation assumptions used in calculating these dollar amounts included in this Annual Report for the fiscal years ended December 31, 2022 and 2021. These amounts reflect our accounting expense for these awards and do not correspond to the actual value that may be recognized by the individuals upon option exercise.

 

 

(2)

Mr. Tangredi’s contract in 2011 stated a salary of $200,000 per year, effective September 14, 2011, and he may receive a bonus in an amount not to exceed 100% of his salary, which bonus shall be measured by meeting certain performance goals as determined in the sole discretion of our board of directors. In 2022 and 2021, Mr. Tangredi was paid $166,367 and $149,359, respectively and had accrued unpaid salary of $32,633 and $51,067 for the years ended December 31, 2022 and 2021, respectively. All other compensation includes accruals for unused vacation, health insurance and auto allowance. As of December 31, 2022, we owed Mr. Tangredi accrued compensation in the aggregate amount of $2,140,687.

 

 
23

Table of Contents

 

Narrative Disclosure to Summary Compensation Table

 

Tim N. Tangredi. The Company entered into an employment agreement with Mr. Tangredi, our President, Chief Executive Officer, and Director, which was amended and restated on September 14, 2011 and subsequently on February 27, 2015 (the “Tangredi Employment Agreement”). The Tangredi Employment Agreement provides for an initial term of three years commencing on September 14, 2011 with the term extending on the second anniversary thereof for an additional two-year period and on each subsequent anniversary of the commencement date for an additional year period. Mr. Tangredi’s initial base salary is $200,000. Mr. Tangredi’s base salary shall be increased annually, if applicable, by a sum equal to his current base salary multiplied by one third of the percentage increase in our yearly revenue compared to our prior fiscal year revenue; provided however any annual increase in Mr. Tangredi’s base salary shall not exceed a maximum of 50% for any given year. Any further increase in Mr. Tangredi’s base salary shall be at the sole discretion of our board of directors or compensation committee (if applicable). In addition, Mr. Tangredi will be eligible for bonus compensation at the discretion of the Board, as well as option-based compensation under our equity compensation plans. Under the Tangredi Employment Agreement, Mr. Tangredi is eligible to receive a grant to purchase up to 520,000 shares of common stock from the Company upon the successful completion of a secondary public offering. For a full description of the Tangredi Employment Agreement please refer to Item 13. Certain Relationships and Related Party Transactions —Employment Agreements below.

 

Outstanding Equity Awards at Fiscal Year End

 

The following table sets forth certain information regarding outstanding stock options awards for each of the Named Executive Officers as of December 31, 2022.

 

Note: In January of 2021 any previous Company issued Options or Warrant to employees, or Board members had been voluntarily returned to the Company.  On January 27, 2022,  the  Board approved the issuance of Series C, D, E, and F convertible preferred warrants, and once approved,  Board further authorized the distribution of Series F Convertible Preferred Warrants to Board members, the Dais Team, and those contractually bound to receive these warrants on January 27, 2022. The four new Series were   approved  by NYS Division of Corporations on March 23, 2022. Series C, and E have been issued to investors as previously reported. Series D, and F are pending issuance. See Subsequent Events for an update.

 

Name

 

 

Number of securities underlying unexercised

options (#) Exercisable

 

 

Option

exercise

price($)

 

 

Option

expiration

date

 

Tim Tangredi

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Brian Johnson

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Kailey M. Humpel

 

 

 

 

 

 

 

 

 

 

 

 
24

Table of Contents

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

 

Beneficial Ownership Information

 

The following table sets forth information as of the date of May 26, 2023, as to each person or group who is known to us to be the beneficial owner of more than 5% of our outstanding voting securities and as to the security and percentage ownership of each of our executive officers and directors and of all of our officers and directors as a group.

 

Name and Address of Beneficial Owner

 

Common

Stock

Owned

Beneficially

 

 

Percent

of Class

 

 

Series B

Preferred

Stock

 

 

Percent

of Class

 

Named Executive Officers and Directors

 

 

 

 

 

 

 

 

 

 

 

 

Tim Tangredi, Officer, Chairman of the Board(1) #

 

 

596

 

 

*

%

 

 

10

 

 

 

100%

Brian Johnson, Chief Technology Officer #

 

 

1

 

 

*

 

 

 

-

 

 

 

-

 

Robert W. Schwartz, Director #

 

 

0

 

 

*

 

 

 

-

 

 

 

-

 

Eliza Wang, Director

 

 

0

 

 

*

 

 

 

-

 

 

 

-

 

Ira William McCollum Jr., Director #

 

 

0

 

 

*

 

 

 

-

 

 

 

-

 

Kailey M. Humpel, Office Manager, Board Secretary #

 

 

0

 

 

*

 

 

 

-

 

 

 

-

 

Rasool Nasr Isfahani, Chief Innovation Officer #

 

 

0

 

 

*

 

 

 

-

 

 

 

-

 

All directors and officers as a group (7 persons)

 

 

597

 

 

*

%

 

 

10

 

 

 

100%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5% or greater shareholders

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

JEB Partners, L.P. (2)

 

 

2,466,667

 

 

 

11

 

 

 

 

 

 

 

 

 

GS Capital Partners LLC (3)

 

 

2,354,811

 

 

 

11

 

 

 

 

 

 

 

 

 

LG Capital Funding LLC (4)

 

 

1,333,741

 

 

 

7

 

 

 

 

 

 

 

 

 

AES Capital Management LLC (5)

 

 

1,222,500

 

 

 

6

 

 

 

 

 

 

 

 

 

Jefferson Street Capital LLC (6)

 

 

1100000

 

 

 

5

 

 

 

 

 

 

 

 

 

Robele Corp (7)

 

 

1000000

 

 

 

5

 

 

 

 

 

 

 

 

 

All 5% or greater shareholders as a group

 

 

9,477,719

 

 

 

44%

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

9,478,316

 

 

 

44%

 

 

10

 

 

 

100%

 

____________

*

Less than 1%

#

Address is Company’s principal office at 11552 Prosperous Driver, Odessa, Florida 33556

(1)

Includes 516 shares beneficially owned by Mr. Tangredi’s wife, Patricia Tangredi.

(2)

The natural person with voting power on behalf of JEB Partners, L.P. is Jeb Besser.

(3)

The natural person with voting power on behalf of GS Capital Partners LLC is Mr. Gabe Sayegh.

(4)

The natural person with voting power on behalf of LG Capital Funding LLC is Mr. Joseph Lerman.

(5)

The natural person with voting power on behalf of AES Capital Management LLC is Mr. Eli Safdieh

(6)

The natural person with voting power on behalf of Jefferson Street Capital LLC is Mr. Brian Goldberg

(7)

The natural person with voting power on behalf of Robele Corp is Mr. Joseph Harazmus

 

Applicable percentage ownership in the preceding table is based on approximately 20,149,365 shares of common stock outstanding as of May 26, 2023 plus, for everyone, any securities that individual has the right to acquire within 60 days of May 26, 2023. Beneficial ownership is determined under the rules of the SEC and generally includes voting or investment power over securities. The number of shares shown as beneficially owned in the tables below are calculated pursuant to Rule 13d-3(d)(1) of the Exchange Act. Under Rule 13d-3(d)(1), shares not outstanding that are subject to options, warrants, rights or conversion privileges exercisable within 60 days are deemed outstanding for the purpose of calculating the number and percentage owned by such person, but not deemed outstanding for the purpose of calculating the percentage owned by each other person listed.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

The following table sets forth information regarding our 2000 Incentive Compensation Plan (the “2000 Plan”), 2009 Long-Term Incentive Plan (the “2009 Plan”) and 2015 Stock Incentive Plan (the “2015 Plan”) under which our securities are authorized for issuance as of December 31, 2021:

 

Plan Category

 

(a) Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights

 

 

(b) Weighted Average Exercise Price of Outstanding Options, Warrants and Rights

 

 

 

 

 

 

 

 

Equity compensation plans approved by security holders

 

 

-

 

 

$-

 

 

 
25

Table of Contents

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS; AND DIRECTOR INDEPENDENCE.

 

Tim Tangredi, our Chief Executive Officer and Chairman, is a founder and a member of the board of directors of Aegis Biosciences, LLC (“Aegis”). Mr. Tangredi currently owns 52% of Aegis’ outstanding equity and spends approximately one week per year on Aegis business for which he is compensated by Aegis. Aegis has two exclusive, world-wide licenses from us under which it has the right to use and sell products containing our polymer technologies in biomedical and health care applications. Pursuant to the second license, Aegis is required to make royalty payments of 1.5% of the net sales price it receives with respect to any personal hygiene product, surgical drape or clothing products (the latter when employed in medical and animal related fields) and license revenue it receives should Aegis grant a sublicense to a third party. Aegis sold no such products, nor has it received any licensing fees requiring a royalty payment be made to us. All obligations for such payments ended on June 2, 2015.

 

The Company rents a building that is owned by two stockholders of the Company, one of which is the Chief Executive Officer. Rent expense for this building is $4,066 per month, including sales tax. The Company recognized rent expense (including property tax charges) related to this lease of $58,333 and $58,015 for the years ended December 31, 2022 and 2021, respectively. The lease term will terminate upon 30 days’ written notice from landlord or 90 days written termination from us.

 

The Company has accrued compensation due to the Chief Executive Officer as of December 31, 2022 and 2021 of $2,140,687 and $2,071,380, respectively, included in accrued compensation and related benefits in the accompanying balance sheets.

 

On June 24, 2016, the Company entered into a Loan and Security Agreement (“Security Agreement”) with Patricia Tangredi (the “Holder”) pursuant to which the Company issued a Senior Secured Promissory Note for $150,000 (the “Note”). The interest rate is 12% per annum compounded daily with a minimum interest payment of $2,000. The Note grants the Holder a secured interest in the assets of the Company. Ms. Tangredi is the wife of Tim N. Tangredi, the Company’s CEO and stockholder, and therefore is a related party of the Company. Pursuant to the Note, the Company is to pay the Holder the principal amount of $150,000 plus all interest due thereon in accordance with terms and conditions of the Security Agreement on the earlier of: (i) the date upon which the Company secures funds, regardless of source, equal to or exceeding, in the aggregate, $1,000,000 or (ii) October 31, 2016 (the “Maturity Date”).

 

During 2016 to the period ended December 31, 2022, the Holder extended the Note pursuant to various amendments. Pursuant to the amendments, the principal amount due was increased to $2,400,499 and interest owed of $3,029,162 with an extension of the   maturity date in negations between the Company and the Secured Noteholder.

 

 
26

Table of Contents

 

Employment Agreements

 

We entered into the following employment agreements with our officers and significant employees:

 

Tim Tangredi - President, Chief Executive Officer, and Director, which was amended and restated on September 14, 2011, and subsequently on February 27, 2015. The documents and any amendments were filed in Form 10-K on March 31, 2016 and in Attachment 10.18.

 

Currently, we have non-interest-bearing accrued compensation due to Mr. Tangredi for deferred salaries earned and unpaid as described above. Pursuant to the February 27, 2015 amendment to the Tangredi Employment Agreement if at any time during a calendar year, the unpaid compensation is greater than $500,000, Mr. Tangredi must convert $100,000 of unpaid compensation into shares of common stock of the Company during such calendar year. The conversion rate shall be equal to 75% of the average closing price for the common stock for the 30 trading days prior to the date of conversion. We shall also pay to Mr. Tangredi a cash payment equal to 20% of the compensation income incurred because of the conversion. Further, at any time any “person” or “group” (as such terms are used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934) becomes the “beneficial owner” (as defined in Rules 13(d)-3 and 13(d)-5 under such Act) of greater of 40% of the then-outstanding voting power of the voting equity interests or a person or group initiate a tender offer for our common stock, Mr. Tangredi may convert unpaid compensation to Class A Convertible Preferred Stock at $1.50 per share. The Board of Directors did not require Mr. Tangredi to convert $100,000 of unpaid compensation into common stock during 2015-2022.

 

Brian Johnson – Chief Technology Officer. The documents and any amendments were filed in the 2019 10-K Fiscal Year ending December 31, 2018 and in Attachment 10.15.

 

Rasool Nasr Isfahani – Chief Innovation Officer. On March 15, 2021 (the “Effective Date”), the Company entered into an employment agreement with Mr. Rasool Nasr Isfahani, pursuant to which Isfahani was appointed as Chief Innovation Officer of the Company. Isfahani’s initial base salary pursuant to the Employment Agreement was $135,000. Isfahani may receive a performance bonus at the discretion of the Board. Isfahani is entitled to participate in any benefits programs offered by the Company and shall be reimbursed for reasonably incurred expenses incurred in the performance of the functions and duties under the Employment Agreement. The initial term of the Employment Agreement was from the Effective Date through March 15, 2022 (the “Initial Term”). Upon expiration of the Initial Term, the Employment Agreement will be automatically extended for additional one-year terms unless Isfahani or the Company shall, upon 30 days written notice to the other, elect not to extend this Employment Agreement for an additional one-year term. Isfahani’s base salary as of December 31, 2022 is $147,000

 

John Walsh – General Manager. On June 15, 2021 (the “Effective Date”), the Company entered into an employment agreement with Mr. Walsh, pursuant to which Walsh was appointed as General Manager of the Company. Walsh’s initial base salary pursuant to the Employment Agreement was $140,000. Walsh may receive a performance bonus at the discretion of the Board. Walsh is entitled to participate in any benefits programs offered by the Company and shall be reimbursed for reasonably incurred expenses incurred in the performance of the functions and duties under the Employment Agreement. The initial term of the Employment Agreement was from the Effective Date through, June 15, 2022, (the “Initial Term”). Upon expiration of the Initial Term, the Employment Agreement will be automatically extended for additional one-year terms unless Walsh or the Company shall, upon 30 days written notice to the other, elect not to extend this Employment Agreement for an additional one-year term.

 

On August 17, 2015 (the “Effective Date”), the Company entered into an employment agreement (the “Johnson Employment Agreement”) with Mr. Brian Johnson (“Johnson”), pursuant to which Johnson was appointed as Chief Technology Officer of the Company. Johnson’s initial base salary pursuant to the Johnson Employment Agreement was $135,000. Johnson may receive a performance bonus at the discretion of the Board. Johnson is entitled to participate in any benefits programs offered by the Company and shall be reimbursed for reasonably incurred expenses incurred in the performance of the functions and duties under the Johnson Employment Agreement. The initial term of the Johnson Employment Agreement was from the Effective Date through February 29, 2016 (the “Initial Term”). Upon expiration of the Initial Term, the Johnson Employment Agreement will be automatically extended for additional one-year terms unless Johnson or the Company shall, upon 30 days written notice to the other, elect not to extend this Agreement for an additional one-year term.

 

 
27

Table of Contents

 

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

 

Audit Fees

 

The aggregate audit fees billed for the years ended December 31, 2022 and 2021 was $36,000 and $54,750, respectively. Audit services include the audits of the financial statements included in our annual reports on Form 10-K and reviews of interim financial statements included in our quarterly reports on Form 10-Q.

 

Audit-Related Fees

 

None.

 

Tax Fees

 

None

 

All Other Fees

 

None

 

Audit Committee Pre-Approval Policies and Procedures

 

The Board has completed a competitive process to review the appointment of the Company's independent registered public accounting firm for the year ending December 31, 2021. As a result of this process, on September 27, 2021, the Board elected to engage Hudgens CPA, PLLC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021 and dismissed RBSM LLP from that role.

 

We do not have an audit committee and, as a result, our Board of Directors evaluates the scope and cost of the engagement before the auditor renders audit or non-audit services. The Board of Directors has considered the services provided by Hudgens CPA, PLLC as disclosed above in the captions audit fees and all other fees and has concluded that such services are compatible with the independence of Hudgens CPA, PLLC as our principal accountant.

 

 
28

Table of Contents

 

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

 

Exhibit

 

 

 

Incorporated by Reference

 

Filed or

Furnished

Number

 

Exhibit Description

 

Form

 

Exhibit

 

Filing Date

 

Herewith

3.1

 

Certificate of Incorporation of The Dais Corporation

 

S-1

 

3.1

 

08/11/2008

 

 

3.2

 

Certificate of Amendment of the Certificate of Incorporation of The Dais Corporation

 

S-1

 

3.2

 

08/11/2008

 

 

3.3

 

Certificate of Amendment of the Certificate of Incorporation of The Dais Corporation

 

S-1

 

3.3

 

08/11/2008

 

 

3.4

 

Certificate of Amendment of the Certificate of Incorporation of The Dais Corporation

 

S-1

 

3.4

 

08/11/2008

 

 

3.5

 

Certificate of Amendment of the Certificate of Incorporation of Dais Analytic Corporation

 

S-1

 

3.5

 

08/11/2008

 

 

3.6

 

Certificate of Amendment of the Certificate of Incorporation of Dais Analytic Corporation

 

S-1

 

3.6

 

08/11/2008

 

 

3.7

 

Certificate of Amendment of the Certificate of Incorporation of Dais Analytic Corporation

 

S-1

 

3.7

 

08/11/2008

 

 

3.8

 

Certificate of Amendment of the Certificate of Incorporation of Dais Analytic Corporation

 

S-1

 

3.8

 

08/11/2008

 

 

3.9

 

Certificate of Amendment of the Certificate of Incorporation of Dais Analytic Corporation

 

8-K

 

3.1

 

03/05/2015

 

 

3.10

 

Certificate of Amendment of the Certificate of Incorporation of Dais Analytic Corporation

 

8-K

 

3.1

 

02/28/2019

 

 

3.11

 

Certificate of Designation

 

 

 

 

 

 

 

 

3.12

 

Bylaws of The Dais Corporation

 

S-1

 

3.9

 

08/11/2008

 

 

10.1

 

Dais Analytic Corporation 2000 Incentive Compensation Plan

 

S-1

 

10.1

 

08/11/2008

 

 

10.2

 

Form of Employee Non-Disclosure and Non-Compete Agreement

 

S-1

 

10.2

 

08/11/2008

 

 

10.3

 

Form of Secured Patent Agreement (Financing)

 

S-1

 

10.11

 

08/11/2008

 

 

10.4

 

Dais Analytic Corporation 2009 Long Term Incentive Plan

 

DEF 14A

 

A

 

10/09/2009

 

 

10.5

 

Executive Compensation Agreement dated April 11, 2011, by and between Dais Analytic Corporation and Timothy N. Tangredi

 

S-1/A

 

10.17

 

04/13/2011

 

 

10.6

 

Executive Compensation Agreement dated September 14, 2011, by and between Dais Analytic Corporation and Timothy N. Tangredi

 

8-K

 

10.1

 

09/15/2011

 

 

10.7

 

Executive Compensation Agreement dated January 11, 2012, by and between Dais Analytic Corporation and Timothy N. Tangredi

 

S-1/A

 

10.28

 

01/13/2012

 

 

10.8

 

Executive Compensation Agreement dated February 27, 2015, by and between Dais Analytic Corporation and Timothy N. Tangredi

 

8-K

 

10.1

 

03/05/2015

 

 

10.10

 

Securities Purchase Agreement dated October 21, 2014, by and between Dais Analytic Corporation and Soex (Hong Kong) Industry & Investment Co., Ltd.

 

8-K

 

10.1

 

01/27/2014

 

 

10.11

 

Distribution Agreement dated April 24, 2014, by and between Dais Analytic Corporation and Soex (Hong Kong) Industry & Investment Co., Ltd.

 

8-K

 

10.1

 

04/28/2014

 

 

10.12

 

Loan and Security Agreement dated June 24, 2016, by and between Dais Analytic Corporation and Patricia K. Tangredi

 

8-K

 

10.1

 

06/28/2016

 

 

10.13

 

Amendment to Senior Secured Promissory Note dated September 7, 2016 by and between Dais Analytic Corporation and Patricia K. Tangredi

 

8-K

 

10.1

 

10/28/2016

 

 

10.14

 

Second Amendment to Senior Secured Promissory Note dated October 30, 2016 by and between Dais Analytic Corporation and Patricia K. Tangredi

 

10-Q

 

10.1

 

11/14/2016

 

 

10.15

 

Employment Agreement dated August 17, 2015, by and between Dais Analytic Corporation and Brian C. Johnson.

 

 

 

 

 

 

 

 

14.1

 

Code of Ethics of Dais Analytic Corporation

 

10-K

 

14.1

 

3/31/2009

 

 

31.1

 

Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a))

 

 

 

 

 

 

 

☒

31.2

 

Certification by the Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a))

 

 

 

 

 

 

 

☒

32.1

 

Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

 

 

☒

32.2

 

Certification by the Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

 

 

☒

101.INS

 

Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).

 

 

 

 

 

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

 

 

 

 

 

 

 

☒

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

 

 

 

 

☒

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

 

 

 

 

☒

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

 

 

 

 

 

☒

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

 

 

 

 

☒

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

 

 

 

 

 

☒

 

 
29

Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

DAIS CORPORATION

 

 

 

 

Date: May 30, 2023

By:

/s/ Tim Tangredi

 

 

 

Tim Tangredi

 

 

 

Chairman of the Board

Chief Executive Officer and Director

(Principal Executive Officer)

(Principal Financial and Accounting Officer)

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacity and on the dates indicated.

 

Signatures

 

Title

 

Date

 

 

 

 

 

/s/ Tim Tangredi

 

Chairman of the Board,

 

May 30, 2023

Tim N. Tangredi

 

Chief Executive Officer and Director

 

 

 

 

 

 

 

/s/ Robert W. Schwartz

 

Director

 

May 30, 2023

Robert W. Schwartz

 

 

 

 

 

 

 

 

 

/s/ Ira William McCollum, Jr.

 

Director

 

May 30, 2023

Ira William McCollum, Jr.

 

 

 

 

 

 

 

 

 

/s/ Eliza Xuan Wang

 

Director

 

May 30, 2023

Eliza Xuan Wang

 

 

 

 

 

 
30

Table of Contents

 

Dais Corporation

(Formerly Dais Analytic Corporation)

Financial Statements

Years Ended December 31, 2022 and 2021

Contents

 

Report of Independent Registered Public Accounting Firm. (ID #6849)

 

F-2

 

 

 

 

 

Financial Statements:

 

 

 

 

 

 

 

Balance Sheets

 

F-3

 

Statements of Operations

 

F-4

 

Statements of Stockholders’ Deficit

 

F-5

 

Statements of Cash Flows

 

F-6

 

Notes to Financial Statements

 

F-7

 

 

 
F-1

Table of Contents

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and

Stockholders of Dais Corporation

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of Dais Corporation (the Company) as of December 31, 2022 and 2021, and the related statements of operations, stockholders’ deficit, and cash flows for each of the years in the two year period ended December 31, 2022, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the two year period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raises substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate. We have determined that there were no critical audit matters.

 

/s/ Hudgens CPA, PLLC

www.hudgenscpas.com

We have served as the Company’s auditor since 2021.

Houston, Texas

May 30, 2023

 

 
F-2

Table of Contents

 

 DAIS CORPORATION

BALANCE SHEETS

 

 

 

December 31,

2022

 

 

December 31,

2021

 

ASSETS

 

 

 

 

 

 

CURRENT ASSETS:

 

 

 

 

 

 

Cash

 

$27,412

 

 

$773,423

 

Accounts receivable, net

 

 

258,708

 

 

 

51,917

 

Inventory

 

 

294,472

 

 

 

72,067

 

Prepaid expenses

 

 

25,871

 

 

 

32,637

 

Total Current Assets

 

 

606,463

 

 

 

930,044

 

Property and equipment, net

 

 

32,400

 

 

 

13,353

 

OTHER ASSETS:

 

 

 

 

 

 

 

 

Deposits

 

 

4,780

 

 

 

4,780

 

Patents, net

 

 

150,048

 

 

 

152,924

 

Total Other Assets

 

 

154,828

 

 

 

157,704

 

TOTAL ASSETS

 

$793,691

 

 

$1,101,101

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

 

 

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

 

 

 

Accounts payable, including related party payables of $298,903 and $282,729 at December 31, 2022 and 2021, respectively

 

$1,401,934

 

 

$922,305

 

Accrued expenses, other, including interest due to related party of $3,031,112 and $2,153,723 at December 31, 2022 and 2021, respectively

 

 

4,018,588

 

 

 

2,945,918

 

Accrued compensation and related benefits

 

 

2,281,414

 

 

 

2,208,692

 

Customer deposits

 

 

305,957

 

 

 

35,306

 

Advance payment received for convertible note

 

 

15,000

 

 

 

15,000

 

Advance payment received for purchase of common stock

 

 

30,000

 

 

 

30,000

 

Notes payable to related parties

 

 

2,410,499

 

 

 

2,174,897

 

Current portion of deferred revenue

 

 

248,656

 

 

 

298,656

 

Note payable - due within one year

 

 

376,000

 

 

 

376,000

 

Convertible notes payable, net of unamortized discount and debt costs of $68,219 and $1,437,838, respectively

 

 

1,986,631

 

 

 

194,162

 

Total Current Liabilities

 

 

13,074,679

 

 

 

9,200,936

 

Notes payable - due after one year

 

 

150,000

 

 

 

272,340

 

Total Liabilities

 

 

13,224,679

 

 

 

9,473,276

 

STOCKHOLDERS’ DEFICIT

 

 

 

 

 

 

 

 

Preferred stock, undesignated; $0.01 par value; 6,130,000 shares authorized; no shares issued and outstanding

 

 

-

 

 

 

-

 

Preferred stock, Series A; $0.01 par value; 2,000,000 shares authorized; no shares issued and outstanding

 

 

-

 

 

 

-

 

Preferred stock, Series B; $0.01 par value; 10,000 shares authorized; 10 shares issued and outstanding at December 31, 2022 and 2021, respectively

 

 

-

 

 

 

-

 

Preferred stock, Series C; $0.01 par value; 100,000 shares authorized; no shares issued and outstanding

 

 

-

 

 

 

-

 

Preferred stock, Series D; $0.01 par value; 10,000 shares authorized; no shares issued and outstanding

 

 

-

 

 

 

-

 

Preferred stock, Series E; $0.01 par value; 250,000 shares authorized; no shares issued and outstanding

 

 

-

 

 

 

-

 

Preferred stock, Series F; $0.01 par value; 1,500,000 shares authorized; no shares issued and outstanding

 

 

-

 

 

 

-

 

Common stock; $0.01 par value; 1,100,000,000 shares authorized; 10,619,331 and 9,415,425 shares issued and 10,618,702 and 9,414,796 shares outstanding at December 31, 2022 and 2021, respectively

 

 

106,193

 

 

 

94,154

 

Common stock to be issued, 1,000,000 and no shares, respectively

 

 

10,000

 

 

 

-

 

Capital in excess of par value

 

 

51,189,596

 

 

 

50,818,885

 

Accumulated deficit

 

 

(62,274,665 )

 

 

(57,823,102 )

 

 

 

(10,968,876 )

 

 

(6,910,063 )

Treasury stock at cost, 629 shares at December 31, 2022 and 2021, respectively

 

 

(1,462,112 )

 

 

(1,462,112 )

Total Stockholders’ Deficit

 

 

(12,430,988 )

 

 

(8,372,175 )

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

$793,691

 

 

$1,101,101

 

 

See accompanying Notes to Financial Statements

 

 
F-3

Table of Contents

 

DAIS CORPORATION

STATEMENTS OF OPERATIONS

 

 

 

For the Years Ended

December 31,

 

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

REVENUE

 

 

 

 

 

 

Sales

 

$1,077,058

 

 

$372,506

 

Royalty and license fees

 

 

50,000

 

 

 

50,000

 

 

 

 

1,127,058

 

 

 

422,506

 

 

 

 

 

 

 

 

 

 

COST OF GOODS SOLD

 

 

977,518

 

 

 

267,837

 

 

 

 

 

 

 

 

 

 

GROSS MARGIN

 

 

149,540

 

 

 

154,669

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

Research and development, net of government grant proceeds of $0 and $89,617 for the years ended December 31, 2022 and 2021, respectively

 

 

328,480

 

 

 

133,808

 

Selling, general and administrative

 

 

1,668,389

 

 

 

1,958,560

 

TOTAL OPERATING EXPENSES

 

 

1,996,869

 

 

 

2,092,368

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(1,847,329 )

 

 

(1,937,699 )

 

 

 

 

 

 

 

 

 

OTHER INCOME (EXPENSE)

 

 

 

 

 

 

 

 

Interest expense

 

 

(2,728,360 )

 

 

(2,065,593 )

Loss on legal judgement

 

 

-

 

 

 

(382,664 )

Forgiveness of debt income

 

 

124,126

 

 

 

146,685

 

Change in fair value of derivative

 

 

-

 

 

 

2,241,678

 

Gain on extinguishment of debt

 

 

-

 

 

 

1,148,554

 

TOTAL OTHER INCOME (EXPENSE), NET

 

 

(2,604,234 )

 

 

1,088,660

 

 

 

 

 

 

 

 

 

 

NET LOSS

 

$(4,451,563 )

 

$(849,039 )

 

 

 

 

 

 

 

 

 

NET LOSS PER COMMON SHARE, BASIC AND DILUTED

 

$(0.43 )

 

$(0.15 )

 

 

 

 

 

 

 

 

 

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED

 

 

10,448,440

 

 

 

5,734,795

 

 

See accompanying Notes to Financial Statements

 

 
F-4

Table of Contents

 

DAIS CORPORATION

STATEMENT OF STOCKHOLDERS’ DEFICIT

FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common

 

 

Capital In

 

 

 

 

 

 

 

 

 

 

 

Preferred

 

 

 

 

 

Common

 

 

 

 

 

Stock

 

 

Excess

 

 

 

 

 

 

Total

 

 

 

Stock

Shares

 

 

Amount

 

 

Stock

Shares

 

 

Amount

 

 

to be

issued

 

 

of Par

Value

 

 

Accumulated

Deficit

 

 

Treasury

Stock

 

 

Stockholders'

Deficit

 

Balance - December 31, 2020

 

 

10

 

 

$-

 

 

 

278,757

 

 

 

2,788

 

 

$-

 

 

$45,976,660

 

 

$(56,974,063)

 

$(1,462,112)

 

$(12,456,727)

Shares and warrants issued for services

 

 

-

 

 

 

-

 

 

 

2,100,000

 

 

 

21,000

 

 

 

-

 

 

 

730,457

 

 

 

-

 

 

 

-

 

 

 

751,457

 

Shares and warrants issued for settlement of debt

 

 

-

 

 

 

-

 

 

 

7,036,668

 

 

 

70,366

 

 

 

-

 

 

 

2,616,768

 

 

 

-

 

 

 

-

 

 

 

2,687,134

 

Warrants issued with debt

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,405,000

 

 

 

-

 

 

 

-

 

 

 

1,405,000

 

Beneficial conversion feature of debt

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

90,000

 

 

 

-

 

 

 

-

 

 

 

90,000

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(849,039)

 

 

-

 

 

 

(849,039)

Balance - December 31, 2021

 

 

10

 

 

 

-

 

 

 

9,415,425

 

 

 

94,154

 

 

 

-

 

 

 

50,818,885

 

 

 

(57,823,102)

 

 

(1,462,112)

 

 

(8,372,175)

Shares issued for conversion of debt and finance cost

 

 

-

 

 

 

-

 

 

 

927,500

 

 

 

9,275

 

 

 

-

 

 

 

83,475

 

 

 

-

 

 

 

-

 

 

 

92,750

 

Cashless exercise of warrants

 

 

-

 

 

 

-

 

 

 

1,276,406

 

 

 

12,764

 

 

 

-

 

 

 

(12,764)

 

 

-

 

 

 

-

 

 

 

-

 

Shares cancelled - to be reissued

 

 

-

 

 

 

-

 

 

 

(1,000,000)

 

 

(10,000)

 

 

10,000

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Beneficial conversion feature of debt

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

300,000

 

 

 

-

 

 

 

-

 

 

 

300,000

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(4,451,563)

 

 

-

 

 

 

(4,451,563)

Balance - December 31, 2022

 

 

10

 

 

$-

 

 

 

10,619,331

 

 

$106,193

 

 

$10,000

 

 

$51,189,596

 

 

$(62,274,665)

 

$(1,462,112)

 

$(12,430,988)

 

See accompanying Notes to Financial Statements

 

 
F-5

Table of Contents

 

DAIS CORPORATION

STATEMENTS OF CASH FLOWS

 

 

 

For the Years Ended

December 31,

 

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net loss

 

$(4,451,563 )

 

$(849,039 )

Adjustments to reconcile net loss to net cash used by operating activities:

 

 

 

 

 

 

 

 

Amortization of deferred debt issue costs

 

 

9,112

 

 

 

1,888

 

Depreciation and amortization

 

 

28,977

 

 

 

21,574

 

Stock based compensation

 

 

750

 

 

 

751,457

 

Change in fair value of derivative liability

 

 

-

 

 

 

(2,241,678 )

Forgiveness of debt

 

 

(122,340 )

 

 

(146,685 )

Non-cash interest expenses

 

 

-

 

 

 

124,290

 

Amortization of debt discount

 

 

1,660,507

 

 

 

324,264

 

Gain on extinguishment of debt

 

 

-

 

 

 

(1,148,554 )

(Increase) decrease in:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(206,791 )

 

 

(51,415 )

Inventory

 

 

(222,405 )

 

 

(6,411 )

Other receivables

 

 

-

 

 

 

6,169

 

Prepaid expenses/Other assets

 

 

6,766

 

 

 

(1,967 )

Increase (decrease) in:

 

 

 

 

 

 

 

 

Accounts payable

 

 

479,629

 

 

 

(62,180 )

Accrued expenses

 

 

1,145,392

 

 

 

2,052,318

 

Customer deposits

 

 

270,651

 

 

 

(7,803 )

Deferred revenue

 

 

(50,000 )

 

 

(50,000 )

Net cash used in operating activities

 

 

(1,451,315 )

 

 

(1,283,772 )

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Purchase of equipment

 

 

(28,035 )

 

 

(11,541 )

Increase in patent costs

 

 

(17,113 )

 

 

(18,217 )

Net cash used in investing activities

 

 

(45,148 )

 

 

(29,758 )

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Proceeds from notes payable - related parties

 

 

482,800

 

 

 

49,297

 

Repayment of notes payable - related parties

 

 

(247,198 )

 

 

-

 

Proceeds from notes payable

 

 

514,850

 

 

 

2,112,340

 

Advance payment for note payable

 

 

-

 

 

 

15,000

 

Advance payment on purchase of common stock

 

 

-

 

 

 

30,000

 

Repayments of notes

 

 

-

 

 

 

(156,200 )

Net cash provided by financing activities

 

 

750,452

 

 

 

2,050,437

 

 

 

 

 

 

 

 

 

 

Net increase (decrease) in cash

 

 

(746,011 )

 

 

736,907

 

Cash, beginning of period

 

 

773,423

 

 

 

36,516

 

Cash, end of period

 

$27,412

 

 

$773,423

 

SUPPLEMENTAL CASH FLOW INFORMATION:

 

 

 

 

 

 

 

 

Cash paid for interest

 

$-

 

 

$744

 

NON-CASH FINANCING AND FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Issuance of common stock and warrants upon settlement of notes and accrued interest

 

$-

 

 

$2,687,134

 

Issuance of common stock upon conversion of notes

 

$92,750

 

 

$-

 

Notes and accrued interest settled with common stock and warrants

 

$-

 

 

$2,107,414

 

Derivative liability extinguished

 

$-

 

 

$1,728,274

 

Relative fair value of warrant, recorded as debt discount

 

$59,998

 

 

$1,405,000

 

Beneficial conversion feature of convertible debt

 

$240,002

 

 

$90,000

 

Common stock to be issued for finance cost, accrued and recorded as debt discount

 

$-

 

 

$120,990

 

Original issued discount, deducted from proceeds and recorded as debt discount

 

$-

 

 

$137,000

 

Debt costs deducted from proceeds of note

 

$-

 

 

$11,000

 

Initial debt discount at issuance of notes

 

$300,000

 

 

$1,752,990

 

 

See accompanying Notes to Financial Statements

 

 
F-6

Table of Contents

 

Dais Corporation

Notes to Financial Statements

Years Ended December 31, 2022 and 2021

 

Note 1. Background Information

 

Dais Corporation (“Dais”, “us,” “we,”, the “Company”), a New York corporation, is a nano-structured polymer technology materials company having developed and now commercializing products using its family of nanomaterial called Aqualyte. Aqualyte itself is the first product being commercialized. The second commercial product is called ConsERV, a fixed plate energy recovery ventilator which we believe is useful in meeting building indoor fresh air requirements while saving energy and lowering emissions for most forms of heating, ventilation, and air conditioning (HVAC) equipment. The Company was incorporated in April 1993 and its corporate headquarters is in Odessa, Florida.

 

The Company is dependent on third parties to manufacture the key components needed for its nanostructured materials and some portion of the value-added products made with these materials. Accordingly, a suppliers’ failure to supply components in a timely manner, or to supply components that meet the Company’s quality, quantity and cost requirements or technical specifications, or the inability to obtain alternative sources of these components on a timely basis or on acceptable terms, would create delays in production of the Company’s products and/or increase its unit costs of production. Certain of the components or the processes of the Company’s suppliers are proprietary. If the Company was ever required to replace any of its suppliers, it should be able to obtain comparable components from alternative suppliers at comparable costs, but this would create a delay in production and may briefly affect the Company’s operations.

 

Note 2. Going Concern and Management’s Plans

 

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. For the year ended December 31, 2022, the Company generated a net loss of $4,451,563 and has incurred significant losses since inception. As of December 31, 2022, the Company has an accumulated deficit of $62,274,665, total stockholders’ deficit of $12,430,988, negative working capital of $12,468,216 and cash and cash equivalents of $27,412. The Company used $1,451,315 and $1,283,772 of cash for operations during the years ended December 31, 2022, and 2021, respectively, which was funded primarily by proceeds from loans from related parties and others. There is no assurance that any such financing will be available in the future. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company is currently pursuing the following sources of short and long-term working capital:

 

 

1.

The Company guided by its Financial Advisors is actively working with targeted third parties who have or are interested in licensing, purchasing the rights to, or establishing a joint venture to commercialize applications of the Company’s technology;

 

 

 

 

2.

The Company continues to seek capital from key strategic and/or government (grant) related sources. These sources may, pursuant to any agreements that may be developed in conjunction with such funding, assist in the product definition and design, roll-out, and channel penetration of products;

 

 

 

 

3.

The Company is actively working with newer investors, private equity companies, purchase order financing parties, and its existing debt holders to restructure its existing debt and obtain short and long-term working and growth capital; and,

 

 

 

 

4.

The Company may license or sell an asset to fund its continued growth as it is clear to management the market for the Company’s  product innovations has changed in a positive way as demonstrated by the interest the Company’s nano-material and applications in certain markets.

 

Management believes:

 

 

1.

The Company’s ability to solve continuing supply chain issues and raise sustainable growth capital will dictate future revenue and cash-flow for the Company. The quicker these issues are resolved we believe the faster the Company can participate in the market’s uptick momentum and follow the projected growth curve.  These issues place heavy pressure on management to progress in key business areas being impacted.   Continued supply chain impacts has roots in the funding challenges. The use of funds from affordable growth capital to resolve inventory levels of hard to acquire parts could be achieved within one quarter. Raising affordable capital is tied to addressing/fixing convertible debt transactions (recently found to be ‘criminally usurious - (Adar v. Geneysy, LLC) used in the past to grow the Company with a plan to replace this convertible debt with lower cost funds. The Company has made progress yet still faces a worldwide public market in turmoil since February of 2022. In the intertest of expediting this situation the Company is seeking affordable public, and non-public, growth resources, with Board approval, is seeking to monetize one asset via a license/supply agreement.  Such a plan (monetize an asset) will require approval by the Company’s Senior Secured Noteholder.

 

 

 

 

2.

The Senior Secured Note Holder has advised Management it is exploring its options to resolve the long standing unpaid – and growing debt by the Company.

 

 

 

 

3.

Ventilation is regularly recommended as one of the solutions to Covid related mitigation and the market awareness for the ConsERV product(s) is increasing and lead activity is encouraging.

 

 

 

 

4.

We believe our current cash position and our projected ability to obtain additional sources of growth capital, and to generate sustainable cash flow from operations and investments into 2023 is improving yet remains challenged.

 

 
F-7

Table of Contents

 

We believe the Company’s prospects to secure growth funding are good. The company has shown solid progress over the last three quarters, removed a serious impediment to growth by completing a ‘debt to equity’ program where the convertible noteholders debt positions were converted into equity (common stock and warrants). The company introduced a popular new line of our ConsERV equipment  having improved performance and pricing to a growing independent sales channel through-out  North America. We reached agreement (now moving to contract stage) in late 4Q 2022 between the company and its Senior Secured Note Holder (having deep rights with the assets of the Company which are pledged as security for repayment of the Note). The company is continuing to develop the basis of a long term business relationship  with a well-known, multi-national corporation interested in using the Company’s products for its own and third-party use. 

 

There are no assurances we will be able to obtain the financing and planned product development commercialization. Accordingly, we may not have the ability to continue as a going concern. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should we be unable to continue as a going concern.

 

Note 3. Significant Accounting Policies

 

The significant accounting policies followed are:

 

Use of estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Significant estimates underlying the Company’s reported financial position and results of operations include the allowance for doubtful accounts, fair value of stock-based compensation, fair value of derivative liabilities, valuation allowance on deferred taxes and the warranty reserve.

 

Revenue recognition - The Company has adopted the new revenue recognition guidelines in accordance with ASC 606, Revenue from Contracts with Customers (ASC 606). The Company analyzes its contracts to assess that they are within the scope and in accordance with ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, whether for goods and services or licensing, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company acts as a principal in its revenue transactions as the Company is the primary obligor in the transactions. Generally, the Company recognizes revenue for its products upon shipment to customers, provided no significant obligations remain and collection is probable.

 

In certain instances, the Company’s ConsERV system product may carry a limited warranty of up to one year for all parts contained therein except for the energy recovery ventilator core produced and sold by the Company. The distributor of the ConsERV system may carry a limited warranty of up to ten years. The limited warranty includes replacement of defective parts for the ConsERV system and includes workmanship and material failure for the ConsERV core. The Company recorded an accrual of $91,531 for future warranty expenses at December 31, 2022 and 2021, which is included in accrued expenses, other.

 

Royalty revenue is recognized as earned. The Company recognized royalty revenue of $0 for the years ended December 31, 2022 and 2021. Revenue derived from the sale of licenses is deferred and recognized as license fee revenue on a straight-line basis over the life of the license, or until the license arrangement is terminated. The Company recognized license fee revenue of $50,000 for each of the years ended December 31, 2022 and 2021.

 

The Company accounts for revenue arrangements with multiple elements under the provisions of the Financial Accounting Standards Boards (FASB) Accounting Standards Codification (ASC) Topic 605-25, “Revenue Recognition-Multiple-Element Arrangements.” In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whether the delivered element has stand-alone value to the licensee. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.

 

 
F-8

Table of Contents

 

In December 2017, the Company and Zhejiang MENRED Environmental Tech Co, Ltd., Zhejiang Province, China (“Menred”), entered into a License and Supply Agreement (the “Agreement”), effective December 21, 2017. Pursuant to the Agreement, the Company licensed certain intellectual property and improvements to Menred, for use in the manufacture and sale of energy recovery ventilators (“ERV”) and certain other HVAC systems for installation in commercial, residential, or industrial buildings in China. Menred also agreed to purchase its requirements of certain products from the Company for Menred’s use, pursuant to the terms and conditions of the Agreement. Menred will also pay royalties, as defined, to the Company on a quarterly basis, based on price and production volume as provided by Menred. No royalties are due within the first year of the Agreement. Also pursuant to the Agreement, the Company is required to purchase a certain amount of Product from Menred.  The Agreement has a ten-year term with mutually agreed upon five-year extensions.

 

Cash and cash equivalents - For purposes of the Statements of Cash Flows, the Company considers all highly liquid debt instruments with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions, and, at times, balances may exceed federally insured limits. The Company had uninsured balances of approximately $0 and $483,000 at December 31, 2022 and 2021, respectively. The Company has never experienced any losses related to these balances. The Company does not have any cash equivalents at December 31, 2022 and 2021.

 

Accounts receivable - Accounts receivable consist primarily of receivables from the sale of the Company’s ERV products and royalties due under license and supply agreements. The Company regularly reviews accounts receivable for any bad debts based on an analysis of the Company’s collection experience, customer credit worthiness and current economic trends. After all attempts to collect a receivable have failed, the receivable is written off against the allowance. Based on management’s review of accounts receivable, no allowance for doubtful accounts was deemed necessary at December 31, 2022 and 2021, respectively.

 

Concentrations - At December 31, 2022, two customers accounted for 76% of accounts receivable. For the year ended December 31, 2022, four customers accounted for 74% of total revenue. For the year ended December 31, 2021, three customers accounted for 73% of total revenue.

 

Other receivables - Other receivables consist primarily of receivables from the U.S. Department of Defense (See Note 3 - Research and development expenses and funding proceeds). The Company prepares invoices as it meets funding program milestones. There were no such receivables at December 31, 2022 and 2021.

 

Fair Value of Financial Instruments - The Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, deferred revenue, customer deposits and notes payable are carried at historical cost. At December 31, 2022 and 2021 the carrying amounts of these instruments approximated their fair values because of the short-term nature of these instruments.

 

Inventory - Inventory consists of raw materials, work-in-process and finished goods and is stated at the lower of cost, determined by first-in, first-out method, or market. Market is determined based on the net realizable value, with appropriate consideration given to obsolescence, excessive levels, deterioration, and other factors. At December 31, 2022 and 2021, the Company had $269,083 and $59,631 of raw materials, $5,997 and $1,844 of in-process inventory and $269,083 and $10,592 of finished goods inventory, respectively. A reserve is recorded for any inventory deemed excessive or obsolete. No reserve is recorded at December 31, 2022 and 2021, respectively.

 

Property and equipment - Property and equipment is recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from 3 to 7 years. Leasehold improvements are amortized over the shorter of their estimated useful lives of 5 years or the related lease term. Depreciation and amortization expense was $8,988 and $2,689 for the years ended December 31, 2022 and 2021, respectively. Gains and losses upon disposition are reflected in the Statement of Operations in the period of disposition. Maintenance and repair expenditures are charged to expense as incurred. There were no dispositions of property and equipment in 2022 or 2021.

 

Intangible assets - Identified intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company’s existing intangible assets consist solely of patents. Patents are amortized over their estimated useful or economic lives of 17 years. Patent amortization expense was $19,989 and $18,885 for the years ended December 31, 2022 and 2021, respectively. Based on current capitalized costs, total patent amortization expense is estimated to be approximately $20,000 per year for the next five years and thereafter.

 

Long-lived assets - Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. The Company periodically evaluates whether events and circumstances have occurred that indicate possible impairment. When impairment indicators exist, the Company estimates the future undiscounted net cash flows of the related asset or asset group over the remaining life in measuring whether the asset values are recoverable. The Company did not recognize impairment on its long-lived assets during the years ended December 31, 2022 or 2021.

 

 
F-9

Table of Contents

 

Government Funding - Government funding represents grants from the U.S. Department of Defense and are recognized when there is reasonable assurance that the funding will be received, and conditions associated with the funding are met. When fundings are received related to property and equipment, the Company reduces the basis of the assets on the balance sheet, resulting in lower depreciation expense over the life of the associated asset. When fundings are received which relate to expense reimbursement they are recorded as a reduction of the associated expense in the period in which the expense is incurred.

 

Research and development expenses and funding proceeds - Expenditures for research, development and engineering of products are expensed as incurred. The Company incurred research and development costs of $328,480 and $223,425 for the years ended December 31, 2022 and 2021, respectively. The Company accounts for proceeds received from government funding’s for research as a reduction in research and development costs. The Company recorded proceeds against research and development expenses on the Statements of Operations of $0 and $89,617 for the years ended December 31, 2022 and 2021, respectively.

 

Derivative Liability - The Company, up until June 30, 2021, had financial instruments that are considered derivatives or contain embedded features subject to derivative accounting. Embedded derivatives are valued separately from the host instrument and are recognized as derivative liabilities in the Company’s balance sheet. The Company measures these instruments at their estimated fair value and recognizes changes in their estimated fair value in results of operations during the period of change.

 

Warranties - The Company offers a limited warranty generally ranging from one to three years, A provision for product warranties has been recorded at December 31, 2022 and 2021. The Company has not incurred any warranty expense in either 2022 or 2021.

 

Stock based compensation - The Company recognizes all share-based payments to employees, including grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period) or immediately if the share-based payments vest immediately.

 

There were no grants in 2022 or 2021.

 

Fair Value Measurements - The Company accounts for financial instruments in accordance with FASB Accounting Standards Codification (ASC) 820 “Fair value Measurement and Disclosures” (ASC 820). ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).

 

The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

 

●

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

 

 

 

●

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g. interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

 

 

 

●

Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

 
F-10

Table of Contents

 

The reconciliation of the derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows for the year ended December 31, 2021:

 

 

 

December 31,

 

 

 

2021

 

Balance, beginning of year

 

$3,845,662

 

Additions

 

 

124,290

 

Extinguished derivative liability

 

 

(1,728,274)

Change in fair value of derivative liabilities

 

 

(2,241,678)

 

 

$

-

 

 

Income taxes - Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes resulting from temporary differences. Such temporary differences result from differences in the carrying value of assets and liabilities for tax and financial reporting purposes. The deferred tax assets and liabilities represent the future tax consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

 

The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s 2017 through 2020 tax years remain open and subject to examination by the Internal Revenue Service.

 

Earnings (loss) per share - Basic income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average common shares outstanding for the period. Diluted income (loss) per share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options and warrants and upon the conversion of notes. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Common share equivalents of 30,212,831 and 32,526,731 were excluded from the computation of diluted earnings per share for the years ended December 31, 2022 and 2021, respectively, because their effect is anti-dilutive.

 

Recent Accounting Pronouncements - Recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

 

Note 4. Property and Equipment

 

Property and equipment consist of the following:

 

 

 

December 31,

 

 

 

2022

 

 

2021

 

Furniture and fixtures

 

$20,966

 

 

$20,966

 

Computer equipment and software

 

 

31,581

 

 

 

21,761

 

Demonstration equipment

 

 

92,733

 

 

 

92,733

 

Office and lab equipment

 

 

310,902

 

 

 

295,987

 

Leasehold improvements

 

 

14,808

 

 

 

14,808

 

Property and equipment, gross

 

 

470,990

 

 

 

446,255

 

Less accumulated depreciation

 

 

438,590

 

 

 

432,902

 

Property and equipment, net

 

$32,400

 

 

$13,353

 

 

Note 5. Accrued Expenses, Other

 

Accrued expenses, other consists of the following:

 

 

 

December 31,

 

 

 

2022

 

 

2021

 

Accrued expenses, other

 

$673,270

 

 

$274,146

 

Accrued interest

 

 

3,253,787

 

 

 

2,197,577

 

Accrued warranty costs

 

 

91,531

 

 

 

91,531

 

 

 

$4,018,588

 

 

$2,945,918

 

 

 
F-11

Table of Contents

 

Note 6. Related Party Transactions

 

The Company rents a building that is owned by two stockholders of the Company, one of which is the Chief Executive Officer. Rent expense for this building is $4,066 per month, including sales tax. The Company recognized rent expense (including property tax charges) related to this lease of $58,333 and $58,015 for the years ended December 31, 2022 and 2021, respectively. The lease term will terminate upon 30 days’ written notice from landlord or 90 days written termination from us. The lease is considered to be short term or month to month.

 

The Company has accrued compensation due to the Chief Executive Officer as of December 31, 2022 and 2021 of $2,140,687 and $2,071,380, respectively, included in accrued compensation and related benefits in the accompanying balance sheets.

 

On June 24, 2016, the Company entered into a Loan and Security Agreement (“Security Agreement”) with the entity known as PKT -- Strategic Assets, LLC (the “Holder”) pursuant to which the Company issued a Senior Secured Promissory Note for $150,000 (the “Note”). The Note has an interest rate is 12% per annum compounded daily with a minimum interest payment of $2,000. The Note grants the Holder a secure interest in all the assets of the Company. During 2016 to the period ended December 31, 2022, the Holder extended the Note pursuant to various amendments. Pursuant to the amendments, the principal amount and interest totaled $5,429,661 and $4,317,270 (including fees and other expenses) at December 31, 2022 and 2021, respectively. We received advances aggregating $482,800 and $49,297 during 2022 and 2021, respectively, and repaid $247,198 during 2022. The Holder’s corporation is controlled by Ms. Tangredi, related to Tim Tangredi: the Company’s CEO and stockholder, and therefore, is a Related Party of the Company. The Company is to pay the Holder the principal, plus all interest and fees due in accordance with terms and conditions of the Security Agreement on the earlier of:

 

(i)

The date upon which the Company secures funds, regardless of source, equal to or exceeding, in the aggregate, $1,000,000 or November 1, 2021, which as of the date of filing, has expired.

(ii)

The Holder has not declared the Note in Default as the Parties have reached terms to address several issues including the extension of the Maturity Date (the “Maturity Date”). The parties have agreed to new language to solve this matter with the plan to have it complete no later than April 30, 2023.

(iii)

The Company has recorded interest expense of $876,789 and $1,473,884 for the years ended December 31, 2022 and 2021, respectively.

(iv)

Accrued interest was $3,029,162 and $2,152,373 at December 31, 2022 and 2021, respectively.

 

On October 12, 2019, the Company entered a promissory note with an entity controlled by our Chief Executive Officer in the amount of $10,000. The note bears interest at 10% per year and matured on October 12, 2021. Interest expense on the note was $600 for each of the years ended December 31, 2022 and 2021. Accrued interest was $1,950 and $1,350 at December 31, 2022 and 2021, respectively. The Holder has not declared the Note in Default or extended the Maturity Date.

 

On April 29, 2022, the Company received a loan of $100,000 from its Chief Executive Officer. This was repaid in full on May 17, 2022.

 

On February 27, 2015, the Company, and Tim N. Tangredi, the Company’s Chief Executive Officer entered an amendment (the “Tangredi Employment Agreement Amendment”) to Mr. Tangredi’s Amended and Restated Employment Agreement. Currently, the Company has non-interest-bearing accrued compensation due to the Chief Executive Officer for deferred salaries earned and unpaid as described above. The Tangredi Employment Agreement Amendment provides that, if at any time during a calendar year, the unpaid compensation is greater than $500,000, Mr. Tangredi must convert $100,000 of unpaid compensation into the Company’s common stock during such calendar year. The conversion rate shall be equal to 75% of the average closing price for the Company’s common stock for the 30 trading days prior to the date of conversion. The Company shall also pay to Mr. Tangredi a cash payment equal to 20% of the compensation income incurred because of the change. The Company has waived the conversion requirement from 2015 to the present.

 

Further, at any time any “person” or “group” (as such terms are used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934) becomes the “beneficial owner” (as defined in Rules 13(d)-3 and 13(d)-5 under such Act) of greater of 40% of the then-outstanding voting power of the voting equity interests of the Company or a person or group initiate a tender offer for the Company’s common stock, Mr. Tangredi may convert unpaid compensation into Class A Convertible Preferred Stock (“Class A Preferred Stock”) of the Company at a conversion price of $1.50 per share. The Board of Directors waived the requirement to convert $100,000 of unpaid compensation into common stock during 2016. No amounts have been converted under the terms of the Tangredi Employment Agreement Amendment to date.

 

On January 27, 2022, the Board approved the distribution of Series F Convertible Preferred Warrants to Board members, the Dais Team, and those contractually bound to receive these warrants on January 27, 2022.  These new Series were approved by NYS Division of Corporations on March 23, 2022.

 

The above terms and amounts are not necessarily indicative of the terms and amounts that would have been incurred had comparable transactions been entered into with independent parties.

 

Note 7. Equity Transactions

 

Preferred Stock

 

On December 31, 2022 and 2021, the Company’s Board of Directors authorized 10,000,000 shares of preferred stock with a par value of $0.01 to be issued in series with terms and conditions to be determined by the Board of Directors.

 

 
F-12

Table of Contents

 

2,000,000 of the shares of preferred stock has been designated as Class A Preferred Stock. The Class A Preferred Stock shall entitle the holder thereof to 150 votes on all matters submitted to a vote of the stockholders of the Company.

 

10,000 of the shares of preferred stock has been designated as Class B Preferred Stock. The Class A Preferred Stock shall entitle the holder thereof to 150 votes on all matters submitted to a vote of the stockholders of the Company. The Class B Stock includes the right to vote in an amount equal to 51% of the votes to approve certain corporate actions, including, without limitation, changing the name of the Company and increasing the number of authorized shares.

 

Upon any liquidation, dissolution or winding up of the Company, no distribution shall be made to the holders of shares of stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Class A or Class B Preferred Stock unless, prior thereto, the holders of shares of Class A or Class B Preferred Stock shall have received $1.50 per share (the “Stated Amount”). The Class A and Class B Preferred Stock shall rank, with respect to the payment of liquidation, dividends and the distribution of assets, senior to the Company’s Common Stock.

 

The Holder (as defined in the Class A Preferred Stock certificate of designations) of the Class A Preferred Stock may convert all or part of the outstanding and unpaid Stated Amount (as defined in the Class A Preferred Stock certificate of designations) into fully paid and non-assessable shares of the Company’s common stock at the Conversion Price (as defined in the Class A Preferred Stock certificate of designations). The number of shares receivable upon conversion equals the Stated Amount divided by the Conversion Price. The Conversion Price shall be equal to 75% of the average closing price for the 30 trading days prior to the election to convert. At no time will the Company convert any of the Stated Amount into common stock if that would result in the Holder beneficially owning more than 49% of the sum of the voting power of the Company’s outstanding shares of common stock plus the voting power of the Class A Preferred Stock. No shares of Class A Preferred Stock have been issued. 

 

The shares of the Class B Preferred Stock shall be automatically redeemed by the Company at $0.01 per share on the date that Tim N. Tangredi ceases, for any reason, to serve as an officer, director, or consultant of the Company.

 

During January and February 2022, after the Company’s fiscal year ended December 31, 2021, the Company’s Board of Directors, with input from the Company’s financial advisors, completed its reevaluation of the Company’s capital structure, including the advisability of authorizing addition series of preferred stock, par value $0.01 (“Preferred Stock”). The Board of Directors determined that it was in the best interests of the Company and its stockholders to authorize four new series of Preferred Stock (sometimes referred to as “New Series of Preferred Stock”).

 

As a result, the Board of Directors and management with the assistance of its outside financial advisors prepared a Certificate of Amendment to its Certificate of Incorporation for the purpose authorizing the four New Series of Preferred Stock, which was subject to the filing by the Company of a Certificate of Amendment with the Department of State of the State of New York (“Certificate of Amendment”).

 

To implement the authorization of the four New Series of Preferred Stock, the Certificate of Amendment was submitted to the Department of State on March 17, 2022, and was accepted for filing on March 22, 2022. The recently authorized New Series of Preferred Stock included: (i) Series C Convertible Preferred Stock, consisting of 100,000 shares, all of which were to be issued following acceptance of the Certificate of Amendment by the Department of State, to two (2) third-party accredited investors who had provided bona fide financial consulting services to the Company; (ii) Series D Convertible Preferred Stock, consisting of 10,000 shares, which shares may be issued, at the sole discretion of the Board of Directors, from time to time, to consultants and other third parties for, among other purposes, new services to the Company and for other good and valuable consideration, none of which shares have been issued; (iii) Series E Convertible Preferred Stock, consisting of 250,000 shares, all of which were to be issued following final acceptance of the Certificate of Amendment by the Department of State, being issued to three (3) “accredited investors” including the Company’s financial advisors in consideration for their capital contributions to the Company; and (iv) Series F Convertible Preferred Stock consisting of 1,500,000 shares which are intended to be issued to several long-tenured key employees and the Company’s Board of Directors in consideration for previously rendered services to the Company as well as to certain noteholders and others under agreements and arrangements that have been authorized by the Board of Directors. Equity issuances within these various classes was to take place during the 4th quarter of 2022 now reset for 1Q of 2023.

 

Common Stock

 

At December 31, 2022, and 2021, the Company’s Board of Directors authorized 1,100,000,000 shares of common stock with a par value of $0.01 to be issued in series with terms and conditions to be determined by the Board of Directors.

 

2022 Common Stock Transactions

 

During May 2022, the Company issued 457,500 shares of common stock upon the conversion of $45,000 of notes payable, plus $750 of costs.

 

 
F-13

Table of Contents

 

During July 2022, the Company issued 470,000 shares of common stock upon the conversion of $47,000 of notes payable.

 

The company issued 1,276,406 shares of common stock upon the cashless exercise of 1,510,000 common stock warrants.

 

The Company cancelled 1,000,000 shares of common stock, which are to be reissued in the future.

 

In connection with a note issued in September 2022, the Company issued a warrant to purchase 1,000,000 shares of common stock to the lender. The warrant has an exercise price of $0.30 per share and expires on September 7, 2027.

 

2021 Common Stock Transactions:

 

During the nine months ended September 30, 2021, the Company issued 7,036,668 shares of common stock and 3,576,733 common stock purchase warrants in settlement of convertible notes payable and related accrued interest. The shares were valued at $1,829,534 and the warrants were valued at $857,600. Of these warrants, 3,266,733 expired during 2022, and 310,000 were exercised on a cashless basis into 203,103 shares of common stock in 2022.

 

During the year ended December 31, 2021, the Company issued 2,100,000 shares of common stock, valued at $567,000, for services.

 

Options and Warrants

 

In January 2021, outstanding Options and Warrants held by Employees, Board Members and the Company’s Secured Note Holder were surrendered by Holders to the Company.

 

The 3,576,733 warrants issued in 2021 in connection with the settlement of debt described in Note 8 have an exercise price of $0.30 per share and expired if unexercised on June 30, 2022. The fair value of the warrants was $857,600, determined using the Black Scholes Model with the following assumptions: (1) risk free interest rate of 0.05%; (2) dividend yield of 0%; (3) volatility factor of the expected market price of the Company’s common stock of 367%; and (4) an expected life of 11.5 months. Of these warrants, 3,266,733 expired during 2022, and 310,000 were exercised on a cashless basis into 203,103 shares of common stock in 2022.

 

During the three months ended June 30, 2021, the Company issued 700,000 warrants for services. The warrants have an exercise price of $0.05 per share and expired on May 18, 2022. The fair value of the warrants was $184,457, determined using the Black Scholes Model with the following assumptions: (1) risk free interest rate of 0.06%; (2) dividend yield of 0%; (3) volatility factor of the expected market price of the Company’s common stock of 376%; and (4) an expected life of 1 year. The 700,000 warrants were exercised on a cashless basis into 676,666 shares of common stock in 2022.

 

In September 2021, the Company issued 1,466,666 warrants in connection with a note in the amount of $220,000. The warrants have an exercise price of $0.15 per share and expire on September 21, 2026. The relative fair value of the warrants was $110,000, determined using the Black Scholes Model with the following assumptions: (1) risk free interest rate of 0.84%; (2) dividend yield of 0%; (3) volatility factor of the expected market price of the Company’s common stock of 389%; and (4) an expected life of 5 years. The Company recorded debt discount of $110,000 related to the warrants.

 

During the fourth quarter of 2021, the Company issued 10,463,332 warrants in connection with convertible notes in the aggregate amount of $1,412,000. The warrants have an exercise price of $0.15 per share and expire five years from the dates of issuance. The relative fair value of the warrants was $1,366,127, determined using the Black Scholes Model with the following assumptions: (1) risk free interest rate of 0.84% - 1.33%; (2) dividend yield of 0%; (3) volatility factor of the expected market price of the Company’s common stock of 386% - 389%; and (4) an expected life of 5 years. The Company recorded debt discount of $1,295,000 related to the warrants, limited to the proceeds received. Of these warrants, 500,000 were exercised on a cashless basis into 396,667 shares of common stock in 2022.

 

In connection with a convertible note issued in September 2022, the Company has issued a warrant to purchase 1,000,000 shares of common stock to the lender. The warrant has an exercise price of $0.30 per share and expires on September 7, 2027. The relative fair value of the warrant was $59,998, determined using the Black Scholes Model with the following assumptions: (1) risk free interest rate of 3.37%; (2) dividend yield of 0%; (3) volatility factor of the expected market price of the Company’s common stock of 360%; and (4) an expected life of 5 years.

 

 
F-14

Table of Contents

 

Note 8. Convertible Notes Payable and Exchange Program

 

Debt to Equity Exchange Program

 

In the period from June 2017 through the end of December 2019, the Company entered eight Convertible Note Holder agreements with eight Note Holders totaling, with all fees, interest, and principal, $2,008,812 as of December 31, 2020. The notes were not considered to be in default and were being renegotiated at March 31, 2021. Subsequently, as of May 31, 2021, each Convertible Noteholder received their fees, interest, and principal totaling $2,107,414 in shares of Common stock of the Company (at $0.030 per share) with 50% warrant coverage (1 year cash warrant with a strike price of 0.30). All documents were executed by June 30, 2021, with all equity/warrants issued by July 31, 2021. The Company issued 7,036,668 Common shares, and 3,576,733 Warrant shares in this transaction. All unexercised warrants expired as of May 15, 2022 per the terms and conditions of the Warrant document.

 

2022 Convertible Notes

 

On December 12, 2022, the Company entered a convertible promissory note in the amount of $40,000. The note matures on the earlier of June 12, 2023 or 5 days after demand and bears interest at 10% per year. The note is convertible into shares of common stock at a fixed conversion price of $0.30 per share.

 

On November 4, 2022, the Company entered a convertible promissory note in the amount of $25,000. The note matures on the earlier of May 4, 2023 or 5 days after demand and bears interest at 10% per year. The note is convertible into shares of common stock at a fixed conversion price of $0.30 per share.

 

On September 7, 2022, the Company entered a convertible promissory note in the amount of $100,000. The note matures on September 7, 2023 and bears interest at 8% per year. In connection with this note, the Company has issued a warrant to purchase 1,000,000 shares of common stock to the lender. The warrant has an exercise price of $0.30 per share and expires on September 7, 2027. The relative fair value of the warrant was $59,998, determined using the Black Scholes Model with the following assumptions: (1) risk free interest rate of 3.37%; (2) dividend yield of 0%; (3) volatility factor of the expected market price of the Company’s common stock of 360%; and (4) an expected life of 5 years. The note is convertible into shares of common stock at a fixed conversion price of $0.10 per share. The company has recorded a beneficial conversion feature of $40,002. Amortization of discount was $31,781 for the year ended December 31, 2022.

 

On August 20, 2022, the Company entered a convertible promissory note in the amount of $49,850. The note matures on the earlier of February 20, 2023 or 10 days after demand and bears interest at 8% per year. The note is convertible into shares of common stock at a fixed conversion price of $0.30 per share.

 

On June 15, 2022, the Company entered two convertible promissory notes aggregating $300,000. The notes mature on the earlier of December 15, 2022 or 10 days after demand and bear interest at 8% per year. The Company received proceeds of $300,000. The notes are convertible into shares of common stock at a fixed conversion price of $0.30 per share. The Company has recorded debt discount of $200,000, related to the beneficial conversion feature of the notes. The discount will be amortized to interest expense over the six-month term of the notes, and $200,000 was amortized during the year ended December 31, 2022, respectively.

 

2021 Convertible Notes

 

On September 20, 2021, the Company entered a convertible promissory note with GS Capital Partners, LLC. The note matured on September 20, 2022 and bears interest at 8% per year. The Company received proceeds of $197,000, after deduction of $20,000 of original issue discount and $3,000 of costs. In connection with this note, the Company has issued a warrant to purchase 1,466,666 shares of common stock to the lender. The warrant has an exercise price of $0.15 per share and expires on September 21, 2026. The relative fair value of the warrant was $110,000, determined using the Black Scholes Model with the following assumptions: (1) risk free interest rate of 0.84%; (2) dividend yield of 0%; (3) volatility factor of the expected market price of the Company’s common stock of 389%; and (4) an expected life of 5 years. The note is convertible into shares of common stock at a fixed conversion price of $0.10 per share. The company has recorded a beneficial conversion feature of $90,000. Amortization of discount and costs was $160,071 and $62,929 for the years ended December 31, 2022 and 2021, respectively. The note matured on September 20, 2022. The lender has not declared a default as both parties are actively discussing a mutually beneficial path forward.  It is expected an agreement will be reached in the fourth quarter of 2022.

 

During the fourth quarter of 2021, the Company entered twenty convertible promissory notes with various holders aggregating $1,412,000. The notes mature one year from issuance and bear interest at 8% per year. The Company received proceeds of $1,287,000, after deduction of $117,000 of original issue discount and $8,000 of costs. In connection with the notes, the Company has issued warrants to purchase 10,463,332 shares of common stock to the lenders. The warrants have an exercise price of $0.15 per share and expire five years from the date of issuance. The relative fair value of the warrants was $1,366,127, determined using the Black Scholes Model with the following assumptions: (1) risk free interest rate of 0.84% - 1.33%; (2) dividend yield of 0%; (3) volatility factor of the expected market price of the Company’s common stock of 386% - 389%; and (4) an expected life of 5 years. The notes are convertible into shares of common stock at a fixed conversion price of $0.10 per share. A total of $1,412,000 has been recorded as debt discount, and 8,000 has been recorded as deferred debt costs. The discount and costs will be amortized to interest expense over the term of the notes Amortization of discount and costs was $1,236,089 and $142,233 for the years ended December 31, 2022 and 2021, respectively.

 

 
F-15

Table of Contents

 

During May 2022, the Company issued 457,500 shares of common stock upon the conversion of $45,000 of notes payable, plus $750 of costs. Unamortized discount and debt costs related to the principal converted were $21,206 and $514, respectively, which were charged against interest expense upon conversion.

 

During July 2022, the Company issued 470,000 shares of common stock upon the conversion of $47,000 of notes payable. Unamortized discount related to the principal converted was $19,958, which was charged against interest expense upon conversion.

 

The Company’s convertible promissory notes at December 30, 2022, and 2021 are as follows:

 

 

 

December 31,

2022

 

 

December 31,

2021

 

Convertible notes payable, bearing interest at 8-10%

 

$2,054,850

 

 

$1,453,960

 

Unamortized debt discount

 

 

(68,219 )

 

 

(1,428,726 )

Unamortized deferred debt issuance cost

 

 

-

 

 

 

(9,112 )

Total

 

 

1,986,631

 

 

 

194,162

 

Current portion

 

$1,986,631

 

 

$194,162

 

 

Note 9. Notes Payable

 

JMS Investments

 

Between April of 2021 and September 30, 2021, JMS Investments of Staten Island, NY, USA invested $376,000 in seven separate transactions. The sums are repayable in the form of one-year demand notes having an interest rate of 8.5%.

 

GEX Management, Inc.

 

On August 30, 2021, the Company entered into a promissory note with GEX Management, Inc. The note matured on February 28, 2022 and bears interest at 10% per year. The note was repaid in December 2021. In connection with this note, the Company has agreed to issue 1,000,000 shares of common stock to the lender. These shares have not been issued at December 31, 2022. The shares to be issued have been valued at $120,990, which has been recorded as debt discount. The discount has been fully amortized in 2021. The value of the shares has been included in accrued expenses at December 31, 2022. 

 

Paycheck Protection Program Loans

 

On January 25, 2021, the Company received $122,340 in a loan borrowed from a bank pursuant to the Paycheck Protection Program under the CARES Act guaranteed by the Small Business Administration (“SBA”), which we expect to be forgiven in part or in full, subject to our compliance with the conditions of the Paycheck Protection Program. If not forgiven, the terms on the note provide for interest at 1% per year and the note mature in 24 months, with 18 monthly payments of $8,146 beginning after the initial 6 month deferral period for payments. The loan and related accrued interest of $1,786 was forgiven on July 12, 2022.

 

On April 29, 2020, the Company received $144,750 in a loan borrowed from a bank pursuant to the Paycheck Protection Program under the CARES Act guaranteed by the Small Business Administration (“SBA”), which we expect to be forgiven in part or in full, subject to our compliance with the conditions of the Paycheck Protection Program. If not forgiven, the terms on the note provide for interest at 1% per year and the note mature in 24 months, with 18 monthly payments of $8,146 beginning after the initial 6 month deferral period for payments. This loan was subsequently forgiven in full on August 29, 2021 and the Company recorded forgiveness of debt income of $146,685, including accrued interest forgiven of $1,935.

 

Small Business Administration Loan

 

On June 12, 2020, the Company received $150,000 in a loan borrowed from the SBA. Installment payments, including principal and interest, of $731 monthly, will begin 12 months from the date of the note. The balance of principal and interest will mature 30 years from the date of the note. Interest will accrue at the rate of 3.75% per year. On March 16, 2021, the U.S. Small Business Administration announced that the deferment period for the repayment would be extended an additional 12 months.

 

 
F-16

Table of Contents

 

Note 10. Derivative Liabilities

 

The Company had identified certain embedded derivatives related to its convertible notes. Since the notes were convertible into a variable number of shares or have a price reset feature, the conversion features of those notes were recorded as derivative liabilities. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date and to adjust to fair value as of each subsequent balance sheet date.

 

The Company has recorded additions to the derivative conversion liabilities related to the conversion feature attributable to interest accrued during the period. These additions totaled $124,290 for the year ended December 31, 2021 and were charged to interest expense.

 

During the year ended December 31, 2021, through the date of settlement of the debt, the Company recorded income of $2,241,678 related to the change in the fair value of the derivatives. The fair value of the embedded derivatives was $1,728,274 at the date of settlement, determined using the Black Scholes Model with the following assumptions: (1) risk free interest rate of 0.01%; (2) dividend yield of 0%; (3) volatility factor of the expected market price of the Company’s common stock of 315%; and (4) an expected life of 3 months.

 

During the second quarter of 2021 the Company issued 7,036,668 shares of common stock, valued at $1,829,534 and 2,826,733 warrants, valued at $857,600, in settlement of $1,453,960 of notes payable and $653,454 of accrued interest. Derivative liability of $1,728,274 was extinguished because of the settlement. The Company recorded a gain on extinguishment of $1,148,554.

 

Note 11. Stock Options and Warrants

 

Options

 

In June 2000 and November 2009, the Company’s Board of Directors adopted, and the shareholders approved, the 2000 Plan and 2009 Plan, respectively (together the “Plans”). The Plans provide for the granting of options to qualified employees of the Company, independent contractors, consultants, directors, and other individuals. The Company’s Board of Directors approved and made available 5,547 and 7,500 shares of common stock to be issued pursuant to the 2000 Plan and the 2009 Plan, respectively. On February 27, 2015, the shareholders approved the Dais Analytic Corporation 2015 Stock Incentive Plan (the “2015 Plan”). The number of shares of common stock reserved for issuance under the 2015 Plan is 5,000. The Plans and the 2015 Plan permit grants of options to purchase common shares authorized and approved by the Company’s Board of Directors. The shares authorized by the Plans have been reduced pursuant to the one-for-2,000 reverse stock split effective December 6, 2019.

 

There were no stock options issued during the years ended December 31, 2022 and 2021.

 

The following summarizes the information relating to outstanding stock options activity during 2022 and 2021:

 

 

 

Common

Shares

 

 

Weighted

Average

Exercise

Price

 

 

Weighted

Average

Remaining

Contractual

Term

(in years)

 

 

Aggregate

Intrinsic

Value

 

Outstanding at December 31, 2020

 

 

9,876

 

 

$230.18

 

 

 

4.8

 

 

$

 

Granted

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

Forfeited or expired

 

 

9,876 )

 

 

230.18

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2020

 

 

-

 

 

 

-

 

 

 

 

 

 

$

 

 

Granted

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

Forfeited or expired

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2021

 

 

-

 

 

$-

 

 

 

 

 

 

$

 

 

Exercisable at December 31, 2021

 

 

-

 

 

$-

 

 

 

 

 

 

$

 

 

 

There was no stock compensation expense related to options for the years ended December 31, 2022 and 2021.

 

 
F-17

Table of Contents

 

Warrants

 

At December 31, 2022, the Company had outstanding warrants to purchase the Company’s common stock which were issued in connection with multiple financing arrangements and consulting agreements. Information relating to these warrants is summarized as follows:

 

 

 

Number of

Shares

 

 

Weighted

Average

Remaining

Life (Years)

 

 

Weighted

Average

Exercise

Price

 

Warrants at December 31, 2020

 

 

239,125

 

 

 

8.7

 

 

$3.41

 

Granted

 

 

16,206,731

 

 

 

 

 

 

 

0.18

 

Forfeited or expired

 

 

(239,125 )

 

 

 

 

 

 

3.41

 

Warrants at December 31, 2021

 

 

16,206,731

 

 

 

3.8

 

 

$0.18

 

Granted

 

 

1,000,000

 

 

 

 

 

 

 

0.30

 

Exercised

 

 

(1,510,000 )

 

 

 

 

 

 

0.13

 

Forfeited or expired

 

 

(3,266,733 )

 

 

 

 

 

 

0.30

 

Warrants at December 31, 2022

 

 

12,429,998

 

 

 

4.0

 

 

$0.16

 

 

Note 12. Deferred Revenue

 

In December 2017, the Company and Zhejiang MENRED Environmental Tech Co, Ltd., Zhejiang Province, China (“Menred”), entered into a royalty bearing License and Supply Agreement (the “License and Supply Agreement”), effective December 21, 2017. Pursuant to the License and Supply Agreement, the Company licensed certain intellectual property and improvements to Menred, for use in the manufacture and sale of certain product types sold by Menred mostly for installation in buildings in China. Menred also agreed to purchase its requirements of certain products from the Company for Menred’s use, pursuant to the terms and conditions of the License and Supply Agreement. Also pursuant to the License and Supply Agreement, each year the Parties have minimum sales commitments of each other’s products. The License and Supply Agreement has a ten-year term with mutually agreed upon five-year extensions. The parties began a renegotiation of the terms and conditions of this agreement in December of 2022.

 

The Company recognized license revenue of $50,000 for each of the years ended December 31, 2022, and 2021. Deferred revenue for the agreement was $248,656 and $298,656 at December 31, 2022 and 2021, respectively. The Company recognized royalty revenue of $0 for the years ended December 31, 2022 and 2021.

 

Note 13. Commitments and Contingencies

 

Litigation

 

From time to time, claims are made against the Company in the ordinary course of its business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties, or injunctions prohibiting the Company from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on the Company’s results of operations for that period or future periods. 

 

In 2015, the Company commenced an action for the cancellation of shares issued to Soex (the “Shares”) in connection with a breached Securities Purchase Agreement and Distribution Agreement entered 2014.

 

The Soex Litigation was tried in U.S. District Court for the Middle District of Florida in October of 2018. The jury at the conclusion of the trial did not award monetary damages to either party for claims or counterclaims.

 

On October 24, 2018, the Company initiated a third lawsuit against an affiliate of Soex, Zhongshan Trans-Tech New Material Technology Co. Ltd. Zhongshan, China, (“Transtech”), and the Chairperson of the affiliate and Soex, based on new information learned by the Company. The Company will seek maximum relief and damages for this on-going and growing illegal misuse the Company’s Intellectual Property. The Company feels this third action will lead in a judgment in favor of the Company.

 

On October 8, 2021 the Company was notified of a unusual order by the Federal District Court judge who oversaw the initial 2018 proceedings. This activity was initiated at the request of Soex’s counsel. The Order awards the defendant (Soex) $300,568 in attorney’s fees and $82,096 in costs for a total award of $382,664 to be paid by Dais. The Order doesn’t specify the date by which the award needs to be paid. The sum is recorded in accrued liabilities.

 

The Company will vigorously defend itself against this Order, as well as move on all possible avenues open to it to stop, what Management believes is an on-going misuse of the Company’s core Intellectual Property. The Company believes - based on the content of the Order and other admissions and actions on the part of others - it has a chance to prevail in an appeal to the benefit of the Company and its shareholders.

 

 
F-18

Table of Contents

 

Accounts Payable

 

The firms below have pursued legal action against the Company to collect overdue accounts payable sums. The Company is working with each to enter into a settlement plan, or “pay over a period of time” payment plan. To date the Company has one agreement in place with SoftinWay.

 

Company

 

Sum Owned

 

 

Payment Plan

 

Legal Action

 

Old Dominion Freight Line (1)

 

$13,575.95

 

 

No

 

Yes

 

Power Plant Services (2)

 

$85,199.11

 

 

No

 

Yes 

 

Softinway (3)

 

$3,350.00

 

 

Yes

 

Yes

 

The O-Ring Store

 

$10,334.00

 

 

No

 

Yes

 

Total

 

$112,459.06

 

 

 

 

 

 

 

Footnotes for Accounts Payable Table

 

 

1.

This action moved towards settlement in December of 2022 and completing in March of 23, 2023. The sum the creditor froze $28,781 of the Company’s funds at the Company’s bank, the parties discussed the matter. The sum owed was agreed to be $17,212 including principle, interest, court costs and legal fees. The agreed sum ($17,212) is in the process of being deducted from the withheld sum at the company's bank. from the withheld $28,781.

 

2.

The sum the creditor froze $4,700 of the Company’s funds at the Company’s bank. The company is exploring post judgement relief options/taking steps to ensure that Secured Noteholders priority is protected and to negotiate an acceptable repayment plan.

 

3.

The original balance of approximately $24,165 has been consistently paid down per a verbal repayment agreement.

 

Note 14. Income Taxes

 

The Company had, subject to limitation, approximately $24.7 million of net operating loss carryforwards at December 31, 2022, of which approximately $18.4 million will expire at various dates beginning in 2021 through 2037. In addition, the Company has research and development tax credits of approximately $409,000 at December 31, 2022 available to offset future taxable income, which will expire from 2030 through 2040. We have provided a 100% valuation allowance for the deferred tax benefits resulting from the net operating loss carryover and our tax credits due to our lack of earnings history. In addressing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. The valuation allowance increased by approximately $200,000 and decreased by approximately $323,000 for the years ended December 31, 2022 and 2021, respectively. Significant components of deferred tax assets and liabilities are as follows:

 

 

 

2022

 

 

2021

 

Deferred revenue

 

$63,000

 

 

$76,000

 

Depreciation

 

 

(5,000 )

 

 

1,000

 

Accrued compensation

 

 

568,000

 

 

 

550,000

 

Research and development credit

 

 

409,000

 

 

 

378,000

 

Accrued warranty and interest expense

 

 

786,000

 

 

 

564,000

 

Net operating loss carryforward

 

 

6,256,000

 

 

 

6,308,000

 

Valuation allowance

 

 

(8,077,000 )

 

 

(7,877,000 )

 

A reconciliation of the federal statutory income tax rate to the Company’s effective income tax rate is as follows:

 

 

 

December 31,

 

 

 

2022

 

 

2021

 

Federal statutory income tax rate

 

 

(21.0 )%

 

 

(21.0 )%

State income taxes, net of federal benefit

 

 

(4.3 )

 

 

(4.3 )

Permanent differences

 

 

21.5

 

 

 

65.2

 

Change in valuation allowance

 

 

3.8

 

 

 

(39.9 )

Provision for income taxes

 

 

0.0%

 

 

0.0%

 

 
F-19

Table of Contents

 

As of December 31, 2022, the Company has not performed an IRC Section 382 study to determine the amount, if any, of its net operating losses that may be limited because of the ownership change percentages during 2022 and prior years. However, the Company will complete the study prior to the utilization of any of its recorded net operating losses.

 

Income tax returns remain open by statue, generally for the years 2019 through 2022.

 

Note 15. Subsequent Events

 

The following material events occurred after December 31, 2022, and as such this requires recognition or disclosure in the financial statements:

 

 

1.

Litigation – SOEX: In early 2023, the Company learned two members of the former Transtech management team allegedly have established two companies to compete with the large Swiss entity still using Dais IP. This is new to the Company and its legal counsel. It is formulating a plan to pursue this matter to the ultimate satisfaction of the Dais shareholders. We remain confident with appropriate counsel the Company will prevail in its reformatted approach to this matter.

 

 

 

 

2.

Financing; During the first quarter of 2023 the Company borrowed from the PKT Strategic Technologies, LLC, Senior Note Holder under the same terms and conditions as the existing sums of money which have been loaned to the Company since June 16, 2016 with principal and interest on these sums for this period remaining to be repaid, the Company increased the amount of its debt to the Senior Note Holder by borrowing $66,000, and $592,960.

 

 

 

 

3.

Financing: During the first quarter of 2023 the company borrowed $350,000 from a related party, but it was repaid in full during the same period. There were no fees or interest incurred. The Company issued 500,000 shares of common stock as part of this agreement.

 

 

 

 

4.

Financing: In March of 2022 the NYS Department of Corporation approved the issuance of Series C, D, E, and F of preferred convertible warrant stock. Series C and E have been issued as outlined in previous reporting. Series D is pending. Series F, for Board members, company employees and those contractually bound to receive these shares, is in the process of being issued.

 

 

 

 

5.

Financing: The company filed a Temporary Restraining Order against four convertible note holders over the terms of its conversion from debt to equity these convertible noteholders. The judge met with the Parties on May 1. It was decided at the conclusion of this meeting to cancel the request for the TRO. More effective tactics are projected to be deployed by the Company to address areas of concern coved in the TRO application.

 

 

 

 

6.

Repayment: In March of 2023 the judgment against the company for Old Dominion Trucking was satisfied. The creditor froze $28,781 of the Company’s funds at the Company’s bank, the parties discussed the matter. The sum owed was agreed to be $17,212 including principle, interest, court costs and legal fees. On May 1, 2023, the Company’s bank refunded the additional $11,444 held.

 

 

 

 

7.

Share issuances: During the first quarter of 2023, the company issued a total of 9,530,034 shares comprising of:

 

·         2,750,939 shares issued for consulting services;

 

·         4,501,959 shares issued for notes payable conversions;

 

·         1,200,000 shares issued as part of obligations in 2022 previously disclosed;

 

·         500,000 shares issued for the $350,000 related party note mentioned in the 3rd subsequent event item and;

 

·         577,500 shares issued for warrant exercises

 

 

 

 

 

 

 

 

8.

Financing: During April 2023, the company received a total of $168,950 from convertible notes payable.

 

No other material events have occurred after December 31, 2022, requiring recognition or disclosure in the financials. 

 

 
F-20

 

Dais (CE) (USOTC:DLYT)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Dais (CE) Charts.
Dais (CE) (USOTC:DLYT)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Dais (CE) Charts.